<!DOCTYPE html>
<html>
<head>
    <meta charset="utf-8">
    <title>Psoriasis is treated by topical Vitamin D, etc.</title>
    <link rel="stylesheet" href="/css/main.css?v=1742566339">
    <link rel="stylesheet" href="/css/pagination.css?v=1742566339">
    <link rel="stylesheet" href="https://cdnjs.cloudflare.com/ajax/libs/font-awesome/6.4.0/css/all.min.css">
    <script src="https://unpkg.com/lunr/lunr.js"></script>
    <script src="/js/search.js?v=1742566339"></script>
</head>
<body>
    <div class="container">
        <div class="sidebar">
            <h2>Search</h2>
            <div class="search-container">
                <input type="text" id="search-input" placeholder="Loading search index..." disabled>
                <div id="search-status" class="search-status">Loading search index...</div>
                <div id="suggestions" class="search-suggestions"></div>
            </div>
            <ul id="search-results"></ul>
            
            <h2>Categories</h2>
            <ul data-spa-nav>
                
                <li><a href="/categories/about-d---introduction/">About D - Introduction (3)</a></li>
                
                <li><a href="/categories/about-d---more-info./">About D - More Info. (3)</a></li>
                
                <li><a href="/categories/adhd/">ADHD (5)</a></li>
                
                <li><a href="/categories/admin-only/">Admin Only (5)</a></li>
                
                <li><a href="/categories/ai/">AI (31)</a></li>
                
                <li><a href="/categories/antibiotics-probiotics/">Antibiotics, Probiotics (4)</a></li>
                
                <li><a href="/categories/associations/">Associations (1)</a></li>
                
                <li><a href="/categories/autism/">Autism (10)</a></li>
                
                <li><a href="/categories/autoimmune/">Autoimmune (9)</a></li>
                
                <li><a href="/categories/back-pain/">Back Pain (3)</a></li>
                
                <li><a href="/categories/better-than-daily/">Better Than Daily (6)</a></li>
                
                <li><a href="/categories/bipolar/">Bipolar (1)</a></li>
                
                <li><a href="/categories/bone---health/">Bone - Health (12)</a></li>
                
                <li><a href="/categories/books-videos-on-vitamin-d/">Books, Videos on Vitamin D (28)</a></li>
                
                <li><a href="/categories/breathing/">Breathing (16)</a></li>
                
                <li><a href="/categories/calcidiol/">Calcidiol (2)</a></li>
                
                <li><a href="/categories/cancer/">Cancer (30)</a></li>
                
                <li><a href="/categories/cancer---after-diagnosis/">Cancer - After Diagnosis (12)</a></li>
                
                <li><a href="/categories/cancer---bladder/">Cancer - Bladder (2)</a></li>
                
                <li><a href="/categories/cancer---breast/">Cancer - Breast (13)</a></li>
                
                <li><a href="/categories/cancer---colon/">Cancer - Colon (8)</a></li>
                
                <li><a href="/categories/cancer---leukemia/">Cancer - Leukemia (1)</a></li>
                
                <li><a href="/categories/cancer---liver/">Cancer - Liver (1)</a></li>
                
                <li><a href="/categories/cancer---lung/">Cancer - Lung (1)</a></li>
                
                <li><a href="/categories/cancer---lymphoma/">Cancer - Lymphoma (1)</a></li>
                
                <li><a href="/categories/cancer---other/">Cancer - Other (7)</a></li>
                
                <li><a href="/categories/cancer---ovarian/">Cancer - Ovarian (2)</a></li>
                
                <li><a href="/categories/cancer---pancreatic/">Cancer - Pancreatic (1)</a></li>
                
                <li><a href="/categories/cancer---prostate/">Cancer - Prostate (4)</a></li>
                
                <li><a href="/categories/cancer---skin/">Cancer - Skin (5)</a></li>
                
                <li><a href="/categories/cardiovascular/">Cardiovascular (35)</a></li>
                
                <li><a href="/categories/category/">Category (1)</a></li>
                
                <li><a href="/categories/cholesterol/">Cholesterol (1)</a></li>
                
                <li><a href="/categories/cognitive/">Cognitive (34)</a></li>
                
                <li><a href="/categories/conference/">Conference (1)</a></li>
                
                <li><a href="/categories/consensus/">Consensus (3)</a></li>
                
                <li><a href="/categories/cost-savings-with-vitamin-d/">Cost Savings With Vitamin D (10)</a></li>
                
                <li><a href="/categories/curcumin/">Curcumin (1)</a></li>
                
                <li><a href="/categories/cyp27b1/">CYP27B1 (6)</a></li>
                
                <li><a href="/categories/cystic-fibrosis/">Cystic Fibrosis (2)</a></li>
                
                <li><a href="/categories/deficiency-of-vitamin-d/">Deficiency of Vitamin D (28)</a></li>
                
                <li><a href="/categories/dental/">Dental (18)</a></li>
                
                <li><a href="/categories/depression/">Depression (17)</a></li>
                
                <li><a href="/categories/diabetes/">Diabetes (23)</a></li>
                
                <li><a href="/categories/epilepsy/">Epilepsy (1)</a></li>
                
                <li><a href="/categories/evidence-for-d/">Evidence for D (7)</a></li>
                
                <li><a href="/categories/falls-and-fractures/">Falls and Fractures (21)</a></li>
                
                <li><a href="/categories/fertility-and-sperm/">Fertility and Sperm (10)</a></li>
                
                <li><a href="/categories/food-sources-for-vitamin-d/">Food Sources for Vitamin D (2)</a></li>
                
                <li><a href="/categories/forms-of-vitamin-d/">Forms of Vitamin D (8)</a></li>
                
                <li><a href="/categories/fortification-with-vitamin-d/">Fortification With Vitamin D (8)</a></li>
                
                <li><a href="/categories/genetics/">Genetics (19)</a></li>
                
                <li><a href="/categories/greger/">Greger (4)</a></li>
                
                <li><a href="/categories/gut/">Gut (13)</a></li>
                
                <li><a href="/categories/headache/">Headache (4)</a></li>
                
                <li><a href="/categories/health/">Health (14)</a></li>
                
                <li><a href="/categories/high-risk/">High Risk (3)</a></li>
                
                <li><a href="/categories/high-dose/">High-Dose (9)</a></li>
                
                <li><a href="/categories/how-much-vitamin-d/">How Much Vitamin D (4)</a></li>
                
                <li><a href="/categories/how-when-to-take-vit.-d/">How, When to Take Vit. D (4)</a></li>
                
                <li><a href="/categories/hypertension/">Hypertension (6)</a></li>
                
                <li><a href="/categories/immunity/">Immunity (13)</a></li>
                
                <li><a href="/categories/increased-use-of-d/">Increased Use of D (2)</a></li>
                
                <li><a href="/categories/infant-child/">Infant-Child (64)</a></li>
                
                <li><a href="/categories/inflammation/">Inflammation (12)</a></li>
                
                <li><a href="/categories/interactions-with-vitamin-d/">Interactions With Vitamin D (11)</a></li>
                
                <li><a href="/categories/intervention/">Intervention (39)</a></li>
                
                <li><a href="/categories/intervention---non-daily/">Intervention - Non Daily (21)</a></li>
                
                <li><a href="/categories/iodine/">Iodine (1)</a></li>
                
                <li><a href="/categories/kidney/">Kidney (7)</a></li>
                
                <li><a href="/categories/liver/">Liver (3)</a></li>
                
                <li><a href="/categories/loading-dose-for-vitamin-d/">Loading Dose for Vitamin D (9)</a></li>
                
                <li><a href="/categories/lupus/">Lupus (3)</a></li>
                
                <li><a href="/categories/meta-analysis-of-vitamin-d/">Meta-Analysis of Vitamin D (52)</a></li>
                
                <li><a href="/categories/metabolic-syndrome/">Metabolic Syndrome (10)</a></li>
                
                <li><a href="/categories/microbiome/">Microbiome (6)</a></li>
                
                <li><a href="/categories/middle-east/">Middle East (2)</a></li>
                
                <li><a href="/categories/mortality-and-d/">Mortality and D (23)</a></li>
                
                <li><a href="/categories/multiple-sclerosis/">Multiple Sclerosis (21)</a></li>
                
                <li><a href="/categories/noontime-sun-and-d/">Noontime Sun and D (11)</a></li>
                
                <li><a href="/categories/obesity/">Obesity (29)</a></li>
                
                <li><a href="/categories/off-topic/">Off Topic (5)</a></li>
                
                <li><a href="/categories/optimum/">Optimum (4)</a></li>
                
                <li><a href="/categories/orient/">Orient (4)</a></li>
                
                <li><a href="/categories/osteoarthritis/">Osteoarthritis (1)</a></li>
                
                <li><a href="/categories/osteoporosis/">Osteoporosis (13)</a></li>
                
                <li><a href="/categories/overview-for-doctors/">Overview for Doctors (1)</a></li>
                
                <li><a href="/categories/pain---chronic/">Pain - Chronic (8)</a></li>
                
                <li><a href="/categories/parkinson/">Parkinson (14)</a></li>
                
                <li><a href="/categories/patent/">Patent (1)</a></li>
                
                <li><a href="/categories/predict-vitamin-d/">Predict Vitamin D (3)</a></li>
                
                <li><a href="/categories/pregnancy/">Pregnancy (48)</a></li>
                
                <li><a href="/categories/psoriasis/">Psoriasis (5)</a></li>
                
                <li><a href="/categories/quality-of-life/">Quality of Life (3)</a></li>
                
                <li><a href="/categories/resveratrol/">Resveratrol (2)</a></li>
                
                <li><a href="/categories/rheumatoid-arthritis/">Rheumatoid Arthritis (6)</a></li>
                
                <li><a href="/categories/rickets/">Rickets (1)</a></li>
                
                <li><a href="/categories/season-of-birth/">Season of Birth (1)</a></li>
                
                <li><a href="/categories/seniors/">Seniors (27)</a></li>
                
                <li><a href="/categories/shut-in/">Shut-In (2)</a></li>
                
                <li><a href="/categories/skin/">Skin (8)</a></li>
                
                <li><a href="/categories/skin---dark/">Skin - Dark (9)</a></li>
                
                <li><a href="/categories/sleep/">Sleep (7)</a></li>
                
                <li><a href="/categories/sports-and-vitamin-d/">Sports and Vitamin D (10)</a></li>
                
                <li><a href="/categories/stroke/">Stroke (12)</a></li>
                
                <li><a href="/categories/supplement/">Supplement (4)</a></li>
                
                <li><a href="/categories/technical-d/">Technical D (1)</a></li>
                
                <li><a href="/categories/tests-for-vitamin-d/">Tests for Vitamin D (3)</a></li>
                
                <li><a href="/categories/thyroid-and-parathyroid/">Thyroid and Parathyroid (1)</a></li>
                
                <li><a href="/categories/top-news/">Top News (7)</a></li>
                
                <li><a href="/categories/toxicity-of-vitamin-d/">Toxicity of Vitamin D (1)</a></li>
                
                <li><a href="/categories/trauma-and-surgery/">Trauma and Surgery (15)</a></li>
                
                <li><a href="/categories/tuberculosis/">Tuberculosis (3)</a></li>
                
                <li><a href="/categories/uv-and-vitamin-d/">UV and Vitamin D (14)</a></li>
                
                <li><a href="/categories/veterinary-and-vitamin-d/">Veterinary and Vitamin D (4)</a></li>
                
                <li><a href="/categories/virus/">Virus (160)</a></li>
                
                <li><a href="/categories/vision/">Vision (14)</a></li>
                
                <li><a href="/categories/vit-d-binding-protein/">Vit D Binding Protein (8)</a></li>
                
                <li><a href="/categories/vitamin-b12/">Vitamin B12 (5)</a></li>
                
                <li><a href="/categories/vitamin-c/">Vitamin C (4)</a></li>
                
                <li><a href="/categories/vitamin-d-and-boron/">Vitamin D and Boron (6)</a></li>
                
                <li><a href="/categories/vitamin-d-and-calcium/">Vitamin D and Calcium (6)</a></li>
                
                <li><a href="/categories/vitamin-d-and-iron/">Vitamin D and Iron (3)</a></li>
                
                <li><a href="/categories/vitamin-d-and-magnesium/">Vitamin D and Magnesium (22)</a></li>
                
                <li><a href="/categories/vitamin-d-and-omega-3/">Vitamin D and Omega-3 (18)</a></li>
                
                <li><a href="/categories/vitamin-d-and-vitamin-a/">Vitamin D and Vitamin A (1)</a></li>
                
                <li><a href="/categories/vitamin-d-and-vitamin-k/">Vitamin D and Vitamin K (8)</a></li>
                
                <li><a href="/categories/vitamin-d-far-from-equator/">Vitamin D Far From Equator (4)</a></li>
                
                <li><a href="/categories/vitamin-d-in-australia-and-new-zealand/">Vitamin D in Australia and New Zealand (2)</a></li>
                
                <li><a href="/categories/vitamin-d-in-canada/">Vitamin D in Canada (2)</a></li>
                
                <li><a href="/categories/vitamin-d-in-europe/">Vitamin D in Europe (4)</a></li>
                
                <li><a href="/categories/vitamin-d-receptor/">Vitamin D Receptor (39)</a></li>
                
                <li><a href="/categories/vitamin-d3-instead-of-d2/">Vitamin D3 Instead of D2 (1)</a></li>
                
                <li><a href="/categories/women/">Women (13)</a></li>
                
                <li><a href="/categories/youth/">Youth (8)</a></li>
                
                <li><a href="/categories/zinc/">Zinc (6)</a></li>
                
            </ul>
        </div>
        <div class="content" role="main">
            
    <article>
        <h1>Psoriasis is treated by topical Vitamin D, etc.</h1>
        <time>May 26, 2023</time>
        <!-- {maketoc Title=""} -->
<hr>
<h4 id="topical-treatment-of-psoriasis-vulgaris">Topical treatment of psoriasis vulgaris</h4>
<p>J Dtsch Dermatol Ges . 2023 May 26. <a href="https://doi.org/10.1111/ddg.15042">doi: 10.1111/ddg.15042</a>   PDF is behind a paywall</p>
<p>Lejla Ramic 1, Paul Sator 1</p>
<p>Topical therapy plays an important role in the treatment of psoriasis. It is the gold standard in mild psoriasis cases and is also recommended in addition to UV and systemic therapy in cases of moderate to severe psoriasis. In this overview article we summarize the current therapeutic options, taking into account special localizations (scalp, facial, intertriginous/genital, or palmoplantar lesions) and situations (hyperkeratotic or inflammatory forms), as well as the therapy options during pregnancy and breastfeeding. In the initial phase, the combination of topical corticosteroids and vitamin D analogues has proven to be the therapy of choice, as well as monotherapy in each case. In maintenance therapy, fixed combination therapy is recommended once or twice a week. In addition to the right choice of active substances, the choice of the right formulation also plays an important role.</p>
<p>To increase adherence, it is very important to consider the personal preferences and experiences of the patient. If topical therapy does not lead to a satisfactory result, additional UV therapy or systemic therapy should be considered.</p>
<h5 id="56-references">56 References</h5>
<ol>
<li>
<p>Nast A, Altenburg A, Augustin M, et al. German S3-Guideline on the treatment of Psoriasis vulgaris, adapted from EuroGuiDerm - Part 1: Treatment goals and treatment recommendations. J Dtsch Dermatol Ges. 2021;19(6):934-1150.</p>
</li>
<li>
<p>Armstrong AW, Read C. Pathophysiology, clinical presentation, and treatment of psoriasis: a review. J Am Med Assoc. 2020;323(19):1945-1960.</p>
</li>
<li>
<p>Boehncke WH, Schön MP. Psoriasis. Lancet. 2015;386(9997):983-994.</p>
</li>
<li>
<p>Mrowietz U, Kragballe K, Reich K, et al. Definition of treatment goals for moderate to severe psoriasis: A European consensus. Arch Dermatol Res. 2011;303(1):1-10.</p>
</li>
<li>
<p>Langenbruch A, Radtke MA, Jacobi A, et al. Quality of psoriasis care in Germany: results of the national health care study “PsoHealth3”. Arch Dermatol Res. 2016;308(6):401-408.</p>
</li>
<li>
<p>Devaux S, Castela A, Archier E, et al. Adherence to  <strong>topical</strong>  treatment in psoriasis: a systematic literature review. J Eur Acad Dermatol Venereol. 2012;26(Suppl 3):61-67.</p>
</li>
<li>
<p>Luger T, Seite S, Humbert P, et al. Recommendations for adjunctive basic skin care in patients with psoriasis. Eur J Dermatol. 2014;24(2):194-200.</p>
</li>
<li>
<p>Fluhr JW, Cavallotti C, Berardesca E. Emollients, moisturizers, and keratolytic agents in psoriasis. Clin Dermatol. 2008;26(4):380-386.</p>
</li>
<li>
<p>M Lebwohl. The role of salicylic acid in the treatment of psoriasis. Int J Dermatol. 1999;38(1):16-24.</p>
</li>
<li>
<p>Taylor JR, Halprin KM. percutaneous absorption of salicylic acid. Arch Dermatol. 1975;111(6):740-743.</p>
</li>
<li>
<p>Lew BL, Cho Y, Kim J, et al. Ceramides and cell signaling molecules in psoriatic epidermis: reduced levels of ceramides, PKC-alpha, and JNK. J Korean Med Sci. 2006;21(1):95-99.</p>
</li>
<li>
<p>Vavrova K, Hrabalek A, Mac-Mary S, et al. Ceramide analogues 142S4 selectively recovers perturbed human skin barrier. Br J Dermatol. 2007; 157(4): 704-712.</p>
</li>
<li>
<p>Levine D, Even-Chen Z, Lipets I, et al. Pilot, multicenter, double-blind, randomized placebo-controlled bilateral comparative study of a combination of calcipotriene and nicotinamide for the treatment of psoriasis. J Am Acad Dermatol. 2010;63(5):775-781.</p>
</li>
<li>
<p>Choudhary V, Kaddour-Djebbar I, Custer VE, et al. Glycerol improves skin lesion development in the imiquimod mouse model of psoriasis: experimental confirmation of anecdotal reports from patients with psoriasis. Int J Mol Sci. 2021;22(16):8749.</p>
</li>
<li>
<p>Seite S. Thermal waters as cosmeceuticals: La Roche-Posay thermal spring water example. Clin Cosmet Investig Dermatol. 2013;6:23-28.</p>
</li>
<li>
<p>Siegfried EC, Jaworski JC, Kaiser JD, Hebert AA. Systematic review of published trials: long-term safety of  <strong>topical corticosteroids</strong>  and  <strong>topical</strong>  calcineurin inhibitors in pediatric patients with atopic dermatitis. BMC Pediatr. 2016;16:75.</p>
</li>
<li>
<p>Douglas WS, Poulin Y, Decroix J, et al. A new calcipotriol/betamethasone formulation with rapid onset of action was superior to monotherapy with betamethasone dipropionate or calcipotriol in psoriasis vulgaris. Acta Derm Venereol. 2002;82:131-135.</p>
</li>
<li>
<p>Papp KA, Guenther L, Boyden B, et al. Early onset of action and efficacy of a combination of calcipotriene and betamethasone dipropionate in the treatment of psoriasis. J Am Acad Dermatol. 2003;48:48-54.</p>
</li>
<li>
<p>Gottlieb AB, Ford RO, Spellman MC. The efficacy and tolerability of clobetasol propionate foam 0.05% in the treatment of mild to moderate plaque-type psoriasis of nonscalp regions. J Cutan Med Surg. 2003;7:185-192.</p>
</li>
<li>
<p>Weston WL, Fennessey PV, Morelli J, et al. Comparison of hypothalamus-pituitary-adrenal axis suppression from superpotent  <strong>topical steroids</strong>  by standard endocrine function testing and gas chromatographic mass spectrometry. J Invest Dermatol. 1988;90:532-535.</p>
</li>
<li>
<p>Wilsmann-Theis D, Gerdes S, Körber A, et al. Topische Therapie der Psoriasis.1. Auflage, Bremen: UNI-MED, 2016.</p>
</li>
<li>
<p>Gerritsen MJ, Van De Kerkhof PC, Langner A. Long-term safety of  <strong>topical</strong>  calcitriol 3 microg g(-1) ointment. Br J Dermatol. 2001;144(Suppl 58):17-19.</p>
</li>
<li>
<p>Amichai B. Psoriasis of the glans penis in a child successfully treated with Elidel (pimecrolimus) cream. J Eur Acad Dermatol Venereol. 2004;18(6):742-743.</p>
</li>
<li>
<p>Freeman AK, Linowski GJ, Brady C, et al. Tacrolimus ointment for the treatment of psoriasis on the face and intertriginous areas. J Am Acad Dermatol. 2003;48(4):564-568.</p>
</li>
<li>
<p>Gribetz C, Ling M, Lebwohl M, et al. Pimecrolimus cream 1% in the treatment of intertriginous psoriasis: A double-blind, randomized study. J Am Acad Dermatol. 2004;51(5):731-738.</p>
</li>
<li>
<p>Remitz A, Reitamo S, Erkko P, et al. Tacrolimus ointment improves psoriasis in a microplaque assay. Br J Dermatol. 1999;141(1):103-107.</p>
</li>
<li>
<p>Zonneveld IM, Rubins A, Jablonska S, et al.  <strong>topical</strong>  tacrolimus is not effective in chronic plaque psoriasis. A pilot study. Arch Dermatol. 1998;134(9):1101-1102.</p>
</li>
<li>
<p>Weischer M, Röcken M, Berneburg M. Calcineurin inhibitors and rapamycin: cancer protection or promotion? Exp Dermatol. 2007;16(5):385-393.</p>
</li>
<li>
<p>Reitamo S, Rissanen J, Remitz A, et al. Tacrolimus ointment does not affect collagen synthesis: results of a single-center randomized trial. J Invest Dermatol. 1998;111(3):396-398.</p>
</li>
<li>
<p>Lebwohl M, Freeman AK, Chapman MS, et al. Tacrolimus ointment is effective for facial and intertriginous psoriasis. J Am Acad Dermatol. 2004;51(5):723-730.</p>
</li>
<li>
<p>Doelker L, Tran C, Gkomouzas A, et al. Production and clearance of cyclobutane dipyrimidine dimers in UV-irradiated skin pretreated with 1% pimecrolimus or 0.1% triamcinolone acetonide creams in normal and atopic patients. Exp Dermatol. 2006;15:342-346.</p>
</li>
<li>
<p>Mrowietz U, Jessat H, Schwarz A, Schwarz T. Anthralin (dithranol) in vitro inhibits human monocytes to secrete IL-6, IL-8 and TNF-α, but not IL-1. Br J Dermatol. 1997;136(4):542-547.</p>
</li>
<li>
<p>Painsi C, Patscheider M, Inzinger M, et al. Die Behandlung der Psoriasis mit klassischer, stationärer Dithranol-Therapie: eine retrospektive Patientenbefragung. J Dtsch Dermatol Ges. 2015;13(11):1156-1163.</p>
</li>
<li>
<p>Vtama (tapinarof) cream, for  <strong>topical</strong>  use. US FDA approved product information; Long Beach, CA: Dermavant Sciences, Inc, 2022.</p>
</li>
<li>
<p>Lebwohl MG, Stein Gold L, Strober B, et al. Phase 3 trials of tapinarof cream for plaque psoriasis. N Engl J Med. 2021;385:2219.</p>
</li>
<li>
<p>Lebwohl MG, Papp KA, Stein Gold L, et al. Trial of roflumilast cream for chronic plaque psoriasis. N Engl J Med. 2020;383(3):229-239.</p>
</li>
<li>
<p>Körber A, Wilsmann-Theis D, Augustun M, et al. Topische Therapie bei Psoriasis vulgaris - ein Behandlungspfad. J Dtsch Dermatol Ges. 2019;17(Suppl 4):3-14.</p>
</li>
<li>
<p>Ruzicka T, Lorenz B. Comparison of calcipotriol monotherapy and a combination of calcipotriol and betamethasone valerate after 2 weeks’ treatment with calcipotriol in the  <strong>topical</strong>  therapy of psoriasis vulgaris: a multicentre, double-blind, randomized study. Br J Dermatol. 1998;138(2):254-258.</p>
</li>
<li>
<p>Kragballe K, Barnes L, Hamberg KJ, et al. Calcipotriol cream with or without concurrent  <strong>topical corticosteroid</strong>  in psoriasis: tolerability and efficacy. Br J Dermatol. 1998;139(4):649-654.</p>
</li>
<li>
<p>Radtke MA, Herberger K, Kornek T, Augustin M. <span>[Calcipotriol plus betamethasone dipropionate gel in the treatment of scalp psoriasis. A review]</span>. Hautarzt. 2010;61(9):770-775.</p>
</li>
<li>
<p>Leonardi C, Bagel J, Yamauchi P, Pariser D, et al. Efficacy and safety of calcipotriene plus betamethasone dipropionate aerosol foam in patients with psoriasis vulgaris - a randomized phase III study (PSO-FAST). J Drugs Dermatol. 2015;14(12):1468-1477.</p>
</li>
<li>
<p>Lebwohl M, Tyring S, Bukhalo M, et al. Fixed combination aerosol foam calcipotriene 0.005% (cal) plus betamethasone dipropionate0.064% (bd) is more efficacious than Cal or BD aerosol foam alone for psoriasis vulgaris: a randomized, double-blind, multicenter, three-arm, phase 2 study. J Clin Aesthet Dermatol. 2016;9(2):34.</p>
</li>
<li>
<p>Koo J, Tyring S, Werschler WP, et al. Superior efficacy of calcipotriene and betamethasone dipropionate aerosol foam versus ointment in patients with psoriasis vulgaris - A randomized phase II study. J Dermatolog Treat. 2016;27(2):120-127.</p>
</li>
<li>
<p>Paul C, Stein Gold L, Cambazard F, et al. Calcipotriol plus betamethasone dipropionate aerosol foam provides superior efficacy vs. gel in patients with psoriasis vulgaris: randomized, controlled PSO-ABLE study. J Eur Acad Dermatol Venereol. 2017;31(1):119-126.</p>
</li>
<li>
<p>Lind M, Nielsen KT, Schefe LH, et al. Supersaturation of calcipotriene and betamethasone dipropionate in a novel aerosol foam formulation for  <strong>topical</strong>  treatment of psoriasis provides enhanced bioavailability of the active ingredients. Dermatol Ther (Heidelb). 2016;6(3):413-425.</p>
</li>
<li>
<p>Samarasekera EJ, Sawyer L, Wonderling D, et al.  <strong>topical</strong>  therapies for the treatment of plaque psoriasis: systematic review and network metaanalyses. Br J Dermatol. 2013;168(5):954-967.</p>
</li>
<li>
<p>Mason AR, Mason J, Cork M, et al.  <strong>topical</strong>  treatments for chronic plaque psoriasis. Cochrane database Syst Rev. 2009;(2):CD005028.</p>
</li>
<li>
<p>Saraceno R, Camplone G, D&rsquo;Agostino M, et al. Efficacy and maintenance strategies of two-compound formulation calcipotriol and betamethasone dipropionate gel (Xamiol® gel) in the treatment of scalp psoriasis: results from a study in 885 patients. J Dermatolog Treat. 2014;25(1):30-33.</p>
</li>
<li>
<p>Stein Gold L, Alonso-Llamazares J, Lacour JP, et al. PSO-LONG: Design of a novel, 12-month clinical trial of  <strong>topical</strong> , proactive maintenance with twice-weekly Cal/BD foam in psoriasis. Adv Ther. 2020;37(11):4730-4753.</p>
</li>
<li>
<p>van de Kerkhof PC, de Hoop D, de Korte J, Kuipers MV. Scalp psoriasis, clinical presentations and therapeutic management. Dermatology. 1998;197(4):326-334.</p>
</li>
<li>
<p>Schlager JG, Rosumeck S, Werner RN, et al.  <strong>topical</strong>  treatments for scalp psoriasis: summary of a Cochrane Systematic Review. Br J Dermatol. 2017;176(3):604-614.</p>
</li>
<li>
<p>Schlager JG, Rosumeck S, Werner RN, et al.  <strong>topical</strong>  treatments for scalp psoriasis. Vol. 2016, Cochrane Database of Systematic Reviews. John Wiley and Sons Ltd. 2016;2:CD009687.</p>
</li>
<li>
<p>Chan CS, Van Voorhees AS, Lebwohl MG, et al. Treatment of severe scalp psoriasis: From the Medical Board of the National Psoriasis Foundation. J Am Acad Dermatol. 2009;60(6):962-971.</p>
</li>
<li>
<p>Jacobi A, Braeutigam M, Mahler V, et al. Pimecrolimus 1% cream in the treatment of facial psoriasis: A 16-week open-label study. Dermatology. 2008;216(2):133-136.</p>
</li>
<li>
<p>Jiaravuthisan MM, Sasseville D, Vender RB, et al. Psoriasis of the nail: Anatomy, pathology, clinical presentation, and a review of the literature on therapy. J Am Acad Dermatol. 2007;57(1):1-27.</p>
</li>
<li>
<p>Williamson L, Dalbeth N, Dockerty JL, et al. Extended report: nail disease in psoriatic arthritis - clinically important, potentially treatable and often overlooked. Rheumatology (Oxford). 2004;43(6):790-794.</p>
</li>
<li>
<p>De Berker D. Management of psoriatic nail disease. Semin Cutan Med Surg. 2009;28(1):39-43.</p>
</li>
<li>
<p>Pasch MC. Nail Psoriasis: A review of treatment options. Drugs. 2016;76(6):675-705.</p>
</li>
<li>
<p>Rigopoulos D, Gregoriou S, Daniel Iii CR, et al. Treatment of nail psoriasis with a two-compound formulation of calcipotriol plus betamethasone dipropionate ointment. Dermatology. 2009;218(4):338-341.</p>
</li>
<li>
<p>Rigopoulos D, Ioannides D, Prastitis N, Katsambas A. Nail psoriasis: a combined treatment using calcipotriol cream and clobetasol propionate cream. Acta Derm Venereol. 2002;82(2):140.</p>
</li>
<li>
<p>Tzung TY, Chen CY, Yang CY, et al. Calcipotriol used as monotherapy or combination therapy with betamethasone dipropionate in the treatment of nail psoriasis. Acta Derm Venereol. 2008;88(3):279-280.</p>
</li>
<li>
<p>Chi CC, Wang SH, Mayon-White R, Wojnarowska F. Pregnancy outcomes after maternal exposure to  <strong>topical corticosteroids</strong> : a UK population-based cohort study. JAMA dermatology. 2013;149(11):1274-1280.</p>
</li>
<li>
<p>Gottlieb AB, Ryan C, Murase JE. Clinical considerations for the management of psoriasis in women. Int J women&rsquo;s dermatology. 2019;5(3):141-150.</p>
</li>
<li>
<p>Chi C., Wang SH, Wojnarowska F, et al. Safety of  <strong>topical corticosteroids</strong>  in pregnancy. Cochrane database Syst Rev. 2015;2015(10).</p>
</li>
<li>
<p>Murase JE, Heller MM, Butler DC. Safety of dermatologic medications in pregnancy and lactation: Part I. Pregnancy. J Am Acad Dermatol. 2014;70(3):401.e1-401.e14.</p>
</li>
<li>
<p>Vestergaard C, Wollenberg A, Barbarot S, et al. European task force on atopic dermatitis position paper: treatment of parental atopic dermatitis during preconception, pregnancy and lactation period. J Eur Acad Dermatol Venereol. 2019;33(9):1644-1659.</p>
</li>
</ol>
<hr>
<h4 id="founder-of-vitamindwiki-on-topical-vitamin-d-for-psoraisis">Founder of VitaminDWiki on Topical vitamin D for psoraisis</h4>
<p>Have been using it for over a decade for small psorasis on my right knee (bik injury)</p>
<p>About 3 times a year I notice it again and re-apply a few drops of nanoemulsion Vitamin D (10,000 IU)</p>
<p>My wife also uses it for skin problems - but washes it off after about 10 minutes . She does not like the sticky feel</p>
<hr>
<h4 id="vitamindwiki--a-hrefpoststopical-vitamin-d-stylecolor-red-text-decoration-underline-titlethis-postcategory-does-not-exist-yet-topical-vitamin-dtopical-vitamin-da-category-contains">VitaminDWiki – <a href="/posts/topical-vitamin-d" style="color: red; text-decoration: underline;" title="This post/category does not exist yet: Topical Vitamin D">Topical Vitamin D</a> category contains</h4>
<hr>
<h4 id="vitamindwiki--psoriasiscategoriespsoriasis-category-contains">VitaminDWiki – <a href="/categories/psoriasis">Psoriasis</a> category contains</h4>
<hr>
<h4 id="renu-mahtani-on-a-hrefpostswonders-of-vitamin-d-renu-mahtani-video-and-transcription-feb-2022oral-treatment--with-vitamin-d-stylecolor-red-text-decoration-underline-titlethis-postcategory-does-not-exist-yet-wonders-of-vitamin-d---renu-mahtani-video-and-transcription---feb-2022oral-treatment-of-psorasis-with-vitamin-dwonders-of-vitamin-d---renu-mahtani-video-and-transcription---feb-2022oral-treatment-of-psorasis-with-vitamin-da">Renu Mahtani on <a href="/posts/wonders-of-vitamin-d-renu-mahtani-video-and-transcription-feb-2022oral-treatment--with-vitamin-d" style="color: red; text-decoration: underline;" title="This post/category does not exist yet: Wonders of Vitamin D - Renu Mahtani video and transcription - Feb 2022|oral treatment of Psorasis with Vitamin D">Wonders of Vitamin D - Renu Mahtani video and transcription - Feb 2022|oral treatment of Psorasis with Vitamin D</a></h4>
<hr>
<h4 id="vitamindwiki--a-hrefpostsnanoemulsion-vitamin-d-may-be-a-substantially-better-form-stylecolor-red-text-decoration-underline-titlethis-postcategory-does-not-exist-yet-nanoemulsion-vitamin-d-may-be-a-substantially-better-formnanoemulsion-vitamin-d-may-be-a-substantially-better-forma-updated-march-2019">VitaminDWiki – <a href="/posts/nanoemulsion-vitamin-d-may-be-a-substantially-better-form" style="color: red; text-decoration: underline;" title="This post/category does not exist yet: Nanoemulsion Vitamin D may be a substantially better form">Nanoemulsion Vitamin D may be a substantially better form</a> updated March 2019</h4>
<hr>
<pre style="background-color: #e0e0e0;">
<code class="language-text">
Markdown:
--------

&lt;!-- {maketoc Title=&quot;&quot;} --&gt;
 

---

#### Topical treatment of psoriasis vulgaris

J Dtsch Dermatol Ges . 2023 May 26. [doi: 10.1111/ddg.15042](https://doi.org/10.1111/ddg.15042) &amp;nbsp; PDF is behind a paywall

Lejla Ramic 1, Paul Sator 1

Topical therapy plays an important role in the treatment of psoriasis. It is the gold standard in mild psoriasis cases and is also recommended in addition to UV and systemic therapy in cases of moderate to severe psoriasis. In this overview article we summarize the current therapeutic options, taking into account special localizations (scalp, facial, intertriginous/genital, or palmoplantar lesions) and situations (hyperkeratotic or inflammatory forms), as well as the therapy options during pregnancy and breastfeeding. In the initial phase, the combination of topical corticosteroids and vitamin D analogues has proven to be the therapy of choice, as well as monotherapy in each case. In maintenance therapy, fixed combination therapy is recommended once or twice a week. In addition to the right choice of active substances, the choice of the right formulation also plays an important role. 

To increase adherence, it is very important to consider the personal preferences and experiences of the patient. If topical therapy does not lead to a satisfactory result, additional UV therapy or systemic therapy should be considered.

##### 56 References

1. Nast A, Altenburg A, Augustin M, et al. German S3-Guideline on the treatment of Psoriasis vulgaris, adapted from EuroGuiDerm - Part 1: Treatment goals and treatment recommendations. J Dtsch Dermatol Ges. 2021;19(6):934-1150.

1. Armstrong AW, Read C. Pathophysiology, clinical presentation, and treatment of psoriasis: a review. J Am Med Assoc. 2020;323(19):1945-1960.

1. Boehncke WH, Schön MP. Psoriasis. Lancet. 2015;386(9997):983-994.

1. Mrowietz U, Kragballe K, Reich K, et al. Definition of treatment goals for moderate to severe psoriasis: A European consensus. Arch Dermatol Res. 2011;303(1):1-10.

1. Langenbruch A, Radtke MA, Jacobi A, et al. Quality of psoriasis care in Germany: results of the national health care study “PsoHealth3”. Arch Dermatol Res. 2016;308(6):401-408.

1. Devaux S, Castela A, Archier E, et al. Adherence to  **topical**  treatment in psoriasis: a systematic literature review. J Eur Acad Dermatol Venereol. 2012;26(Suppl 3):61-67.

1. Luger T, Seite S, Humbert P, et al. Recommendations for adjunctive basic skin care in patients with psoriasis. Eur J Dermatol. 2014;24(2):194-200.

1. Fluhr JW, Cavallotti C, Berardesca E. Emollients, moisturizers, and keratolytic agents in psoriasis. Clin Dermatol. 2008;26(4):380-386.

1. M Lebwohl. The role of salicylic acid in the treatment of psoriasis. Int J Dermatol. 1999;38(1):16-24.

1. Taylor JR, Halprin KM. percutaneous absorption of salicylic acid. Arch Dermatol. 1975;111(6):740-743.

1. Lew BL, Cho Y, Kim J, et al. Ceramides and cell signaling molecules in psoriatic epidermis: reduced levels of ceramides, PKC-alpha, and JNK. J Korean Med Sci. 2006;21(1):95-99.

1. Vavrova K, Hrabalek A, Mac-Mary S, et al. Ceramide analogues 142S4 selectively recovers perturbed human skin barrier. Br J Dermatol. 2007; 157(4): 704-712.

1. Levine D, Even-Chen Z, Lipets I, et al. Pilot, multicenter, double-blind, randomized placebo-controlled bilateral comparative study of a combination of calcipotriene and nicotinamide for the treatment of psoriasis. J Am Acad Dermatol. 2010;63(5):775-781.

1. Choudhary V, Kaddour-Djebbar I, Custer VE, et al. Glycerol improves skin lesion development in the imiquimod mouse model of psoriasis: experimental confirmation of anecdotal reports from patients with psoriasis. Int J Mol Sci. 2021;22(16):8749.

1. Seite S. Thermal waters as cosmeceuticals: La Roche-Posay thermal spring water example. Clin Cosmet Investig Dermatol. 2013;6:23-28.

1. Siegfried EC, Jaworski JC, Kaiser JD, Hebert AA. Systematic review of published trials: long-term safety of  **topical corticosteroids**  and  **topical**  calcineurin inhibitors in pediatric patients with atopic dermatitis. BMC Pediatr. 2016;16:75.

1. Douglas WS, Poulin Y, Decroix J, et al. A new calcipotriol/betamethasone formulation with rapid onset of action was superior to monotherapy with betamethasone dipropionate or calcipotriol in psoriasis vulgaris. Acta Derm Venereol. 2002;82:131-135.

1. Papp KA, Guenther L, Boyden B, et al. Early onset of action and efficacy of a combination of calcipotriene and betamethasone dipropionate in the treatment of psoriasis. J Am Acad Dermatol. 2003;48:48-54.

1. Gottlieb AB, Ford RO, Spellman MC. The efficacy and tolerability of clobetasol propionate foam 0.05% in the treatment of mild to moderate plaque-type psoriasis of nonscalp regions. J Cutan Med Surg. 2003;7:185-192.

1. Weston WL, Fennessey PV, Morelli J, et al. Comparison of hypothalamus-pituitary-adrenal axis suppression from superpotent  **topical steroids**  by standard endocrine function testing and gas chromatographic mass spectrometry. J Invest Dermatol. 1988;90:532-535.

1. Wilsmann-Theis D, Gerdes S, Körber A, et al. Topische Therapie der Psoriasis.1. Auflage, Bremen: UNI-MED, 2016.

1. Gerritsen MJ, Van De Kerkhof PC, Langner A. Long-term safety of  **topical**  calcitriol 3 microg g(-1) ointment. Br J Dermatol. 2001;144(Suppl 58):17-19.

1. Amichai B. Psoriasis of the glans penis in a child successfully treated with Elidel (pimecrolimus) cream. J Eur Acad Dermatol Venereol. 2004;18(6):742-743.

1. Freeman AK, Linowski GJ, Brady C, et al. Tacrolimus ointment for the treatment of psoriasis on the face and intertriginous areas. J Am Acad Dermatol. 2003;48(4):564-568.

1. Gribetz C, Ling M, Lebwohl M, et al. Pimecrolimus cream 1% in the treatment of intertriginous psoriasis: A double-blind, randomized study. J Am Acad Dermatol. 2004;51(5):731-738.

1. Remitz A, Reitamo S, Erkko P, et al. Tacrolimus ointment improves psoriasis in a microplaque assay. Br J Dermatol. 1999;141(1):103-107.

1. Zonneveld IM, Rubins A, Jablonska S, et al.  **topical**  tacrolimus is not effective in chronic plaque psoriasis. A pilot study. Arch Dermatol. 1998;134(9):1101-1102.

1. Weischer M, Röcken M, Berneburg M. Calcineurin inhibitors and rapamycin: cancer protection or promotion? Exp Dermatol. 2007;16(5):385-393.

1. Reitamo S, Rissanen J, Remitz A, et al. Tacrolimus ointment does not affect collagen synthesis: results of a single-center randomized trial. J Invest Dermatol. 1998;111(3):396-398.

1. Lebwohl M, Freeman AK, Chapman MS, et al. Tacrolimus ointment is effective for facial and intertriginous psoriasis. J Am Acad Dermatol. 2004;51(5):723-730.

1. Doelker L, Tran C, Gkomouzas A, et al. Production and clearance of cyclobutane dipyrimidine dimers in UV-irradiated skin pretreated with 1% pimecrolimus or 0.1% triamcinolone acetonide creams in normal and atopic patients. Exp Dermatol. 2006;15:342-346.

1. Mrowietz U, Jessat H, Schwarz A, Schwarz T. Anthralin (dithranol) in vitro inhibits human monocytes to secrete IL-6, IL-8 and TNF-α, but not IL-1. Br J Dermatol. 1997;136(4):542-547.

1. Painsi C, Patscheider M, Inzinger M, et al. Die Behandlung der Psoriasis mit klassischer, stationärer Dithranol-Therapie: eine retrospektive Patientenbefragung. J Dtsch Dermatol Ges. 2015;13(11):1156-1163.

1. Vtama (tapinarof) cream, for  **topical**  use. US FDA approved product information; Long Beach, CA: Dermavant Sciences, Inc, 2022.

1. Lebwohl MG, Stein Gold L, Strober B, et al. Phase 3 trials of tapinarof cream for plaque psoriasis. N Engl J Med. 2021;385:2219.

1. Lebwohl MG, Papp KA, Stein Gold L, et al. Trial of roflumilast cream for chronic plaque psoriasis. N Engl J Med. 2020;383(3):229-239.

1. Körber A, Wilsmann-Theis D, Augustun M, et al. Topische Therapie bei Psoriasis vulgaris - ein Behandlungspfad. J Dtsch Dermatol Ges. 2019;17(Suppl 4):3-14.

1. Ruzicka T, Lorenz B. Comparison of calcipotriol monotherapy and a combination of calcipotriol and betamethasone valerate after 2 weeks’ treatment with calcipotriol in the  **topical**  therapy of psoriasis vulgaris: a multicentre, double-blind, randomized study. Br J Dermatol. 1998;138(2):254-258.

1. Kragballe K, Barnes L, Hamberg KJ, et al. Calcipotriol cream with or without concurrent  **topical corticosteroid**  in psoriasis: tolerability and efficacy. Br J Dermatol. 1998;139(4):649-654.

1. Radtke MA, Herberger K, Kornek T, Augustin M. &lt;span&gt;[Calcipotriol plus betamethasone dipropionate gel in the treatment of scalp psoriasis. A review]&lt;/span&gt;. Hautarzt. 2010;61(9):770-775.

1. Leonardi C, Bagel J, Yamauchi P, Pariser D, et al. Efficacy and safety of calcipotriene plus betamethasone dipropionate aerosol foam in patients with psoriasis vulgaris - a randomized phase III study (PSO-FAST). J Drugs Dermatol. 2015;14(12):1468-1477.

1. Lebwohl M, Tyring S, Bukhalo M, et al. Fixed combination aerosol foam calcipotriene 0.005% (cal) plus betamethasone dipropionate0.064% (bd) is more efficacious than Cal or BD aerosol foam alone for psoriasis vulgaris: a randomized, double-blind, multicenter, three-arm, phase 2 study. J Clin Aesthet Dermatol. 2016;9(2):34.

1. Koo J, Tyring S, Werschler WP, et al. Superior efficacy of calcipotriene and betamethasone dipropionate aerosol foam versus ointment in patients with psoriasis vulgaris - A randomized phase II study. J Dermatolog Treat. 2016;27(2):120-127.

1. Paul C, Stein Gold L, Cambazard F, et al. Calcipotriol plus betamethasone dipropionate aerosol foam provides superior efficacy vs. gel in patients with psoriasis vulgaris: randomized, controlled PSO-ABLE study. J Eur Acad Dermatol Venereol. 2017;31(1):119-126.

1. Lind M, Nielsen KT, Schefe LH, et al. Supersaturation of calcipotriene and betamethasone dipropionate in a novel aerosol foam formulation for  **topical**  treatment of psoriasis provides enhanced bioavailability of the active ingredients. Dermatol Ther (Heidelb). 2016;6(3):413-425.

1. Samarasekera EJ, Sawyer L, Wonderling D, et al.  **topical**  therapies for the treatment of plaque psoriasis: systematic review and network metaanalyses. Br J Dermatol. 2013;168(5):954-967.

1. Mason AR, Mason J, Cork M, et al.  **topical**  treatments for chronic plaque psoriasis. Cochrane database Syst Rev. 2009;(2):CD005028.

1. Saraceno R, Camplone G, D&#39;Agostino M, et al. Efficacy and maintenance strategies of two-compound formulation calcipotriol and betamethasone dipropionate gel (Xamiol® gel) in the treatment of scalp psoriasis: results from a study in 885 patients. J Dermatolog Treat. 2014;25(1):30-33.

1. Stein Gold L, Alonso-Llamazares J, Lacour JP, et al. PSO-LONG: Design of a novel, 12-month clinical trial of  **topical** , proactive maintenance with twice-weekly Cal/BD foam in psoriasis. Adv Ther. 2020;37(11):4730-4753.

1. van de Kerkhof PC, de Hoop D, de Korte J, Kuipers MV. Scalp psoriasis, clinical presentations and therapeutic management. Dermatology. 1998;197(4):326-334.

1. Schlager JG, Rosumeck S, Werner RN, et al.  **topical**  treatments for scalp psoriasis: summary of a Cochrane Systematic Review. Br J Dermatol. 2017;176(3):604-614.

1. Schlager JG, Rosumeck S, Werner RN, et al.  **topical**  treatments for scalp psoriasis. Vol. 2016, Cochrane Database of Systematic Reviews. John Wiley and Sons Ltd. 2016;2:CD009687.

1. Chan CS, Van Voorhees AS, Lebwohl MG, et al. Treatment of severe scalp psoriasis: From the Medical Board of the National Psoriasis Foundation. J Am Acad Dermatol. 2009;60(6):962-971.

1. Jacobi A, Braeutigam M, Mahler V, et al. Pimecrolimus 1% cream in the treatment of facial psoriasis: A 16-week open-label study. Dermatology. 2008;216(2):133-136.

1. Jiaravuthisan MM, Sasseville D, Vender RB, et al. Psoriasis of the nail: Anatomy, pathology, clinical presentation, and a review of the literature on therapy. J Am Acad Dermatol. 2007;57(1):1-27.

1. Williamson L, Dalbeth N, Dockerty JL, et al. Extended report: nail disease in psoriatic arthritis - clinically important, potentially treatable and often overlooked. Rheumatology (Oxford). 2004;43(6):790-794.

1. De Berker D. Management of psoriatic nail disease. Semin Cutan Med Surg. 2009;28(1):39-43.

1. Pasch MC. Nail Psoriasis: A review of treatment options. Drugs. 2016;76(6):675-705.

1. Rigopoulos D, Gregoriou S, Daniel Iii CR, et al. Treatment of nail psoriasis with a two-compound formulation of calcipotriol plus betamethasone dipropionate ointment. Dermatology. 2009;218(4):338-341.

1. Rigopoulos D, Ioannides D, Prastitis N, Katsambas A. Nail psoriasis: a combined treatment using calcipotriol cream and clobetasol propionate cream. Acta Derm Venereol. 2002;82(2):140.

1. Tzung TY, Chen CY, Yang CY, et al. Calcipotriol used as monotherapy or combination therapy with betamethasone dipropionate in the treatment of nail psoriasis. Acta Derm Venereol. 2008;88(3):279-280.

1. Chi CC, Wang SH, Mayon-White R, Wojnarowska F. Pregnancy outcomes after maternal exposure to  **topical corticosteroids** : a UK population-based cohort study. JAMA dermatology. 2013;149(11):1274-1280.

1. Gottlieb AB, Ryan C, Murase JE. Clinical considerations for the management of psoriasis in women. Int J women&#39;s dermatology. 2019;5(3):141-150.

1. Chi C., Wang SH, Wojnarowska F, et al. Safety of  **topical corticosteroids**  in pregnancy. Cochrane database Syst Rev. 2015;2015(10).

1. Murase JE, Heller MM, Butler DC. Safety of dermatologic medications in pregnancy and lactation: Part I. Pregnancy. J Am Acad Dermatol. 2014;70(3):401.e1-401.e14.

1. Vestergaard C, Wollenberg A, Barbarot S, et al. European task force on atopic dermatitis position paper: treatment of parental atopic dermatitis during preconception, pregnancy and lactation period. J Eur Acad Dermatol Venereol. 2019;33(9):1644-1659.

---

#### Founder of VitaminDWiki on Topical vitamin D for psoraisis

Have been using it for over a decade for small psorasis on my right knee (bik injury)

About 3 times a year I notice it again and re-apply a few drops of nanoemulsion Vitamin D (10,000 IU)

My wife also uses it for skin problems - but washes it off after about 10 minutes . She does not like the sticky feel

---

#### VitaminDWiki – &lt;a href=&quot;/posts/topical-vitamin-d&quot; style=&quot;color: red; text-decoration: underline;&quot; title=&quot;This post/category does not exist yet: Topical Vitamin D&quot;&gt;Topical Vitamin D&lt;/a&gt; category contains

---

#### VitaminDWiki – [Psoriasis](/categories/psoriasis) category contains

---

#### Renu Mahtani on &lt;a href=&quot;/posts/wonders-of-vitamin-d-renu-mahtani-video-and-transcription-feb-2022oral-treatment--with-vitamin-d&quot; style=&quot;color: red; text-decoration: underline;&quot; title=&quot;This post/category does not exist yet: Wonders of Vitamin D - Renu Mahtani video and transcription - Feb 2022|oral treatment of Psorasis with Vitamin D&quot;&gt;Wonders of Vitamin D - Renu Mahtani video and transcription - Feb 2022|oral treatment of Psorasis with Vitamin D&lt;/a&gt;

---

#### VitaminDWiki – &lt;a href=&quot;/posts/nanoemulsion-vitamin-d-may-be-a-substantially-better-form&quot; style=&quot;color: red; text-decoration: underline;&quot; title=&quot;This post/category does not exist yet: Nanoemulsion Vitamin D may be a substantially better form&quot;&gt;Nanoemulsion Vitamin D may be a substantially better form&lt;/a&gt; updated March 2019

 - - - - - - - - - - - - - -



AST Structure:
-------------
├── DivNode
│   full_match: `{DIV(class=&quot;lefth4&quot;)}{maketoc Title=&quot;&quot;}{DIV}`
│   inner_content: `{maketoc Title=&quot;&quot;}`
│   attrs_dict:
│   │   raw_content: (class=&quot;lefth4&quot;)
│   │   class: lefth4
│   children:
│   ├── MakeTocNode
│   │   full_match: `{maketoc Title=&quot;&quot;}`
│   │   inner_content: ``
│   │   attrs_dict:
│   │   │   raw_content:  Title=&quot;&quot;
│   │   │   Title: ├── TextNode
│   full_match: ` `
│   inner_content: ` `├── HorizontalRuleNode
│   full_match: `\n---\n`
│   inner_content: `---`├── HeadingNode
│   full_match: `!!!!Topical treatment of psoriasis vulgaris`
│   inner_content: `Topical treatment of psoriasis vulgaris`
│   level: `4`
│   children:
│   ├── TextNode
│   │   full_match: `Topical treatment of psoriasis vulgaris`
│   │   inner_content: `Topical treatment of psoriasis vulgaris`├── TextNode
│   full_match: `\nJ Dtsch Dermatol Ges . 2023 May 26. `
│   inner_content: `\nJ Dtsch Dermatol Ges . 2023 May 26. `├── DoiLinkNode
│   full_match: `doi: 10.1111/ddg.15042`
│   inner_content: `10.1111/ddg.15042`├── TextNode
│   full_match: ` `
│   inner_content: ` `├── HorizontalSpaceNode
│   full_match: `~hs~`
│   inner_content: ``
│   repetitions: `1`├── TextNode
│   full_match: ` PDF is behind a paywall\nLejla Ramic 1, Paul Sator 1\n\nTopical therapy plays an important role in the treatment of psoriasis. It is the gold standard in mild psoriasis cases and is also recommended in addition to UV and systemic therapy in cases of moderate to severe psoriasis. In this overview article we summarize the current therapeutic options, taking into account special localizations (scalp, facial, intertriginous/genital, or palmoplantar lesions) and situations (hyperkeratotic or inflammatory forms), as well as the therapy options during pregnancy and breastfeeding. In the initial phase, the combination of topical corticosteroids and vitamin D analogues has proven to be the therapy of choice, as well as monotherapy in each case. In maintenance therapy, fixed combination therapy is recommended once or twice a week. In addition to the right choice of active substances, the choice of the right formulation also plays an important role. \nTo increase adherence, it is very important to consider the personal preferences and experiences of the patient. If topical therapy does not lead to a satisfactory result, additional UV therapy or systemic therapy should be considered.\n`
│   inner_content: ` PDF is behind a paywall\nLejla Ramic 1, Paul Sator 1\n\nTopical therapy plays an important role in the treatment of psoriasis. It is the gold standard in mild psoriasis cases and is also recommended in addition to UV and systemic therapy in cases of moderate to severe psoriasis. In this overview article we summarize the current therapeutic options, taking into account special localizations (scalp, facial, intertriginous/genital, or palmoplantar lesions) and situations (hyperkeratotic or inflammatory forms), as well as the therapy options during pregnancy and breastfeeding. In the initial phase, the combination of topical corticosteroids and vitamin D analogues has proven to be the therapy of choice, as well as monotherapy in each case. In maintenance therapy, fixed combination therapy is recommended once or twice a week. In addition to the right choice of active substances, the choice of the right formulation also plays an important role. \nTo increase adherence, it is very important to consider the personal preferences and experiences of the patient. If topical therapy does not lead to a satisfactory result, additional UV therapy or systemic therapy should be considered.\n`├── HeadingNode
│   full_match: `\n!!!!!56 References`
│   inner_content: `56 References`
│   level: `5`
│   children:
│   ├── TextNode
│   │   full_match: `56 References`
│   │   inner_content: `56 References`├── TextNode
│   full_match: `\n`
│   inner_content: `\n`├── NumListItemNode
│   full_match: `#Nast A, Altenburg A, Augustin M, et al. German S3-Guideline on the treatment of Psoriasis vulgaris, adapted from EuroGuiDerm - Part 1: Treatment goals and treatment recommendations. J Dtsch Dermatol Ges. 2021;19(6):934-1150.`
│   inner_content: `Nast A, Altenburg A, Augustin M, et al. German S3-Guideline on the treatment of Psoriasis vulgaris, adapted from EuroGuiDerm - Part 1: Treatment goals and treatment recommendations. J Dtsch Dermatol Ges. 2021;19(6):934-1150.`
│   depth: `1`
│   children:
│   ├── TextNode
│   │   full_match: `Nast A, Altenburg A, Augustin M, et al. German S3-Guideline on the treatment of Psoriasis vulgaris, adapted from EuroGuiDerm - Part 1: Treatment goals and treatment recommendations. J Dtsch Dermatol Ges. 2021;19(6):934-1150.`
│   │   inner_content: `Nast A, Altenburg A, Augustin M, et al. German S3-Guideline on the treatment of Psoriasis vulgaris, adapted from EuroGuiDerm - Part 1: Treatment goals and treatment recommendations. J Dtsch Dermatol Ges. 2021;19(6):934-1150.`├── TextNode
│   full_match: `\n`
│   inner_content: `\n`├── NumListItemNode
│   full_match: `#Armstrong AW, Read C. Pathophysiology, clinical presentation, and treatment of psoriasis: a review. J Am Med Assoc. 2020;323(19):1945-1960.`
│   inner_content: `Armstrong AW, Read C. Pathophysiology, clinical presentation, and treatment of psoriasis: a review. J Am Med Assoc. 2020;323(19):1945-1960.`
│   depth: `1`
│   children:
│   ├── TextNode
│   │   full_match: `Armstrong AW, Read C. Pathophysiology, clinical presentation, and treatment of psoriasis: a review. J Am Med Assoc. 2020;323(19):1945-1960.`
│   │   inner_content: `Armstrong AW, Read C. Pathophysiology, clinical presentation, and treatment of psoriasis: a review. J Am Med Assoc. 2020;323(19):1945-1960.`├── TextNode
│   full_match: `\n`
│   inner_content: `\n`├── NumListItemNode
│   full_match: `#Boehncke WH, Schön MP. Psoriasis. Lancet. 2015;386(9997):983-994.`
│   inner_content: `Boehncke WH, Schön MP. Psoriasis. Lancet. 2015;386(9997):983-994.`
│   depth: `1`
│   children:
│   ├── TextNode
│   │   full_match: `Boehncke WH, Schön MP. Psoriasis. Lancet. 2015;386(9997):983-994.`
│   │   inner_content: `Boehncke WH, Schön MP. Psoriasis. Lancet. 2015;386(9997):983-994.`├── TextNode
│   full_match: `\n`
│   inner_content: `\n`├── NumListItemNode
│   full_match: `#Mrowietz U, Kragballe K, Reich K, et al. Definition of treatment goals for moderate to severe psoriasis: A European consensus. Arch Dermatol Res. 2011;303(1):1-10.`
│   inner_content: `Mrowietz U, Kragballe K, Reich K, et al. Definition of treatment goals for moderate to severe psoriasis: A European consensus. Arch Dermatol Res. 2011;303(1):1-10.`
│   depth: `1`
│   children:
│   ├── TextNode
│   │   full_match: `Mrowietz U, Kragballe K, Reich K, et al. Definition of treatment goals for moderate to severe psoriasis: A European consensus. Arch Dermatol Res. 2011;303(1):1-10.`
│   │   inner_content: `Mrowietz U, Kragballe K, Reich K, et al. Definition of treatment goals for moderate to severe psoriasis: A European consensus. Arch Dermatol Res. 2011;303(1):1-10.`├── TextNode
│   full_match: `\n`
│   inner_content: `\n`├── NumListItemNode
│   full_match: `#Langenbruch A, Radtke MA, Jacobi A, et al. Quality of psoriasis care in Germany: results of the national health care study “PsoHealth3”. Arch Dermatol Res. 2016;308(6):401-408.`
│   inner_content: `Langenbruch A, Radtke MA, Jacobi A, et al. Quality of psoriasis care in Germany: results of the national health care study “PsoHealth3”. Arch Dermatol Res. 2016;308(6):401-408.`
│   depth: `1`
│   children:
│   ├── TextNode
│   │   full_match: `Langenbruch A, Radtke MA, Jacobi A, et al. Quality of psoriasis care in Germany: results of the national health care study “PsoHealth3”. Arch Dermatol Res. 2016;308(6):401-408.`
│   │   inner_content: `Langenbruch A, Radtke MA, Jacobi A, et al. Quality of psoriasis care in Germany: results of the national health care study “PsoHealth3”. Arch Dermatol Res. 2016;308(6):401-408.`├── TextNode
│   full_match: `\n`
│   inner_content: `\n`├── NumListItemNode
│   full_match: `#Devaux S, Castela A, Archier E, et al. Adherence to __topical__ treatment in psoriasis: a systematic literature review. J Eur Acad Dermatol Venereol. 2012;26(Suppl 3):61-67.`
│   inner_content: `Devaux S, Castela A, Archier E, et al. Adherence to __topical__ treatment in psoriasis: a systematic literature review. J Eur Acad Dermatol Venereol. 2012;26(Suppl 3):61-67.`
│   depth: `1`
│   children:
│   ├── TextNode
│   │   full_match: `Devaux S, Castela A, Archier E, et al. Adherence to `
│   │   inner_content: `Devaux S, Castela A, Archier E, et al. Adherence to `
│   ├── BoldNode
│   │   full_match: `__topical__`
│   │   inner_content: `topical`
│   │   children:
│   │   ├── TextNode
│   │   │   full_match: `topical`
│   │   │   inner_content: `topical`
│   ├── TextNode
│   │   full_match: ` treatment in psoriasis: a systematic literature review. J Eur Acad Dermatol Venereol. 2012;26(Suppl 3):61-67.`
│   │   inner_content: ` treatment in psoriasis: a systematic literature review. J Eur Acad Dermatol Venereol. 2012;26(Suppl 3):61-67.`├── TextNode
│   full_match: `\n`
│   inner_content: `\n`├── NumListItemNode
│   full_match: `#Luger T, Seite S, Humbert P, et al. Recommendations for adjunctive basic skin care in patients with psoriasis. Eur J Dermatol. 2014;24(2):194-200.`
│   inner_content: `Luger T, Seite S, Humbert P, et al. Recommendations for adjunctive basic skin care in patients with psoriasis. Eur J Dermatol. 2014;24(2):194-200.`
│   depth: `1`
│   children:
│   ├── TextNode
│   │   full_match: `Luger T, Seite S, Humbert P, et al. Recommendations for adjunctive basic skin care in patients with psoriasis. Eur J Dermatol. 2014;24(2):194-200.`
│   │   inner_content: `Luger T, Seite S, Humbert P, et al. Recommendations for adjunctive basic skin care in patients with psoriasis. Eur J Dermatol. 2014;24(2):194-200.`├── TextNode
│   full_match: `\n`
│   inner_content: `\n`├── NumListItemNode
│   full_match: `#Fluhr JW, Cavallotti C, Berardesca E. Emollients, moisturizers, and keratolytic agents in psoriasis. Clin Dermatol. 2008;26(4):380-386.`
│   inner_content: `Fluhr JW, Cavallotti C, Berardesca E. Emollients, moisturizers, and keratolytic agents in psoriasis. Clin Dermatol. 2008;26(4):380-386.`
│   depth: `1`
│   children:
│   ├── TextNode
│   │   full_match: `Fluhr JW, Cavallotti C, Berardesca E. Emollients, moisturizers, and keratolytic agents in psoriasis. Clin Dermatol. 2008;26(4):380-386.`
│   │   inner_content: `Fluhr JW, Cavallotti C, Berardesca E. Emollients, moisturizers, and keratolytic agents in psoriasis. Clin Dermatol. 2008;26(4):380-386.`├── TextNode
│   full_match: `\n`
│   inner_content: `\n`├── NumListItemNode
│   full_match: `#M Lebwohl. The role of salicylic acid in the treatment of psoriasis. Int J Dermatol. 1999;38(1):16-24.`
│   inner_content: `M Lebwohl. The role of salicylic acid in the treatment of psoriasis. Int J Dermatol. 1999;38(1):16-24.`
│   depth: `1`
│   children:
│   ├── TextNode
│   │   full_match: `M Lebwohl. The role of salicylic acid in the treatment of psoriasis. Int J Dermatol. 1999;38(1):16-24.`
│   │   inner_content: `M Lebwohl. The role of salicylic acid in the treatment of psoriasis. Int J Dermatol. 1999;38(1):16-24.`├── TextNode
│   full_match: `\n`
│   inner_content: `\n`├── NumListItemNode
│   full_match: `#Taylor JR, Halprin KM. percutaneous absorption of salicylic acid. Arch Dermatol. 1975;111(6):740-743.`
│   inner_content: `Taylor JR, Halprin KM. percutaneous absorption of salicylic acid. Arch Dermatol. 1975;111(6):740-743.`
│   depth: `1`
│   children:
│   ├── TextNode
│   │   full_match: `Taylor JR, Halprin KM. percutaneous absorption of salicylic acid. Arch Dermatol. 1975;111(6):740-743.`
│   │   inner_content: `Taylor JR, Halprin KM. percutaneous absorption of salicylic acid. Arch Dermatol. 1975;111(6):740-743.`├── TextNode
│   full_match: `\n`
│   inner_content: `\n`├── NumListItemNode
│   full_match: `#Lew BL, Cho Y, Kim J, et al. Ceramides and cell signaling molecules in psoriatic epidermis: reduced levels of ceramides, PKC-alpha, and JNK. J Korean Med Sci. 2006;21(1):95-99.`
│   inner_content: `Lew BL, Cho Y, Kim J, et al. Ceramides and cell signaling molecules in psoriatic epidermis: reduced levels of ceramides, PKC-alpha, and JNK. J Korean Med Sci. 2006;21(1):95-99.`
│   depth: `1`
│   children:
│   ├── TextNode
│   │   full_match: `Lew BL, Cho Y, Kim J, et al. Ceramides and cell signaling molecules in psoriatic epidermis: reduced levels of ceramides, PKC-alpha, and JNK. J Korean Med Sci. 2006;21(1):95-99.`
│   │   inner_content: `Lew BL, Cho Y, Kim J, et al. Ceramides and cell signaling molecules in psoriatic epidermis: reduced levels of ceramides, PKC-alpha, and JNK. J Korean Med Sci. 2006;21(1):95-99.`├── TextNode
│   full_match: `\n`
│   inner_content: `\n`├── NumListItemNode
│   full_match: `#Vavrova K, Hrabalek A, Mac-Mary S, et al. Ceramide analogues 142S4 selectively recovers perturbed human skin barrier. Br J Dermatol. 2007; 157(4): 704-712.`
│   inner_content: `Vavrova K, Hrabalek A, Mac-Mary S, et al. Ceramide analogues 142S4 selectively recovers perturbed human skin barrier. Br J Dermatol. 2007; 157(4): 704-712.`
│   depth: `1`
│   children:
│   ├── TextNode
│   │   full_match: `Vavrova K, Hrabalek A, Mac-Mary S, et al. Ceramide analogues 142S4 selectively recovers perturbed human skin barrier. Br J Dermatol. 2007; 157(4): 704-712.`
│   │   inner_content: `Vavrova K, Hrabalek A, Mac-Mary S, et al. Ceramide analogues 142S4 selectively recovers perturbed human skin barrier. Br J Dermatol. 2007; 157(4): 704-712.`├── TextNode
│   full_match: `\n`
│   inner_content: `\n`├── NumListItemNode
│   full_match: `#Levine D, Even-Chen Z, Lipets I, et al. Pilot, multicenter, double-blind, randomized placebo-controlled bilateral comparative study of a combination of calcipotriene and nicotinamide for the treatment of psoriasis. J Am Acad Dermatol. 2010;63(5):775-781.`
│   inner_content: `Levine D, Even-Chen Z, Lipets I, et al. Pilot, multicenter, double-blind, randomized placebo-controlled bilateral comparative study of a combination of calcipotriene and nicotinamide for the treatment of psoriasis. J Am Acad Dermatol. 2010;63(5):775-781.`
│   depth: `1`
│   children:
│   ├── TextNode
│   │   full_match: `Levine D, Even-Chen Z, Lipets I, et al. Pilot, multicenter, double-blind, randomized placebo-controlled bilateral comparative study of a combination of calcipotriene and nicotinamide for the treatment of psoriasis. J Am Acad Dermatol. 2010;63(5):775-781.`
│   │   inner_content: `Levine D, Even-Chen Z, Lipets I, et al. Pilot, multicenter, double-blind, randomized placebo-controlled bilateral comparative study of a combination of calcipotriene and nicotinamide for the treatment of psoriasis. J Am Acad Dermatol. 2010;63(5):775-781.`├── TextNode
│   full_match: `\n`
│   inner_content: `\n`├── NumListItemNode
│   full_match: `#Choudhary V, Kaddour-Djebbar I, Custer VE, et al. Glycerol improves skin lesion development in the imiquimod mouse model of psoriasis: experimental confirmation of anecdotal reports from patients with psoriasis. Int J Mol Sci. 2021;22(16):8749.`
│   inner_content: `Choudhary V, Kaddour-Djebbar I, Custer VE, et al. Glycerol improves skin lesion development in the imiquimod mouse model of psoriasis: experimental confirmation of anecdotal reports from patients with psoriasis. Int J Mol Sci. 2021;22(16):8749.`
│   depth: `1`
│   children:
│   ├── TextNode
│   │   full_match: `Choudhary V, Kaddour-Djebbar I, Custer VE, et al. Glycerol improves skin lesion development in the imiquimod mouse model of psoriasis: experimental confirmation of anecdotal reports from patients with psoriasis. Int J Mol Sci. 2021;22(16):8749.`
│   │   inner_content: `Choudhary V, Kaddour-Djebbar I, Custer VE, et al. Glycerol improves skin lesion development in the imiquimod mouse model of psoriasis: experimental confirmation of anecdotal reports from patients with psoriasis. Int J Mol Sci. 2021;22(16):8749.`├── TextNode
│   full_match: `\n`
│   inner_content: `\n`├── NumListItemNode
│   full_match: `#Seite S. Thermal waters as cosmeceuticals: La Roche-Posay thermal spring water example. Clin Cosmet Investig Dermatol. 2013;6:23-28.`
│   inner_content: `Seite S. Thermal waters as cosmeceuticals: La Roche-Posay thermal spring water example. Clin Cosmet Investig Dermatol. 2013;6:23-28.`
│   depth: `1`
│   children:
│   ├── TextNode
│   │   full_match: `Seite S. Thermal waters as cosmeceuticals: La Roche-Posay thermal spring water example. Clin Cosmet Investig Dermatol. 2013;6:23-28.`
│   │   inner_content: `Seite S. Thermal waters as cosmeceuticals: La Roche-Posay thermal spring water example. Clin Cosmet Investig Dermatol. 2013;6:23-28.`├── TextNode
│   full_match: `\n`
│   inner_content: `\n`├── NumListItemNode
│   full_match: `#Siegfried EC, Jaworski JC, Kaiser JD, Hebert AA. Systematic review of published trials: long-term safety of __topical corticosteroids__ and __topical__ calcineurin inhibitors in pediatric patients with atopic dermatitis. BMC Pediatr. 2016;16:75.`
│   inner_content: `Siegfried EC, Jaworski JC, Kaiser JD, Hebert AA. Systematic review of published trials: long-term safety of __topical corticosteroids__ and __topical__ calcineurin inhibitors in pediatric patients with atopic dermatitis. BMC Pediatr. 2016;16:75.`
│   depth: `1`
│   children:
│   ├── TextNode
│   │   full_match: `Siegfried EC, Jaworski JC, Kaiser JD, Hebert AA. Systematic review of published trials: long-term safety of `
│   │   inner_content: `Siegfried EC, Jaworski JC, Kaiser JD, Hebert AA. Systematic review of published trials: long-term safety of `
│   ├── BoldNode
│   │   full_match: `__topical corticosteroids__`
│   │   inner_content: `topical corticosteroids`
│   │   children:
│   │   ├── TextNode
│   │   │   full_match: `topical corticosteroids`
│   │   │   inner_content: `topical corticosteroids`
│   ├── TextNode
│   │   full_match: ` and `
│   │   inner_content: ` and `
│   ├── BoldNode
│   │   full_match: `__topical__`
│   │   inner_content: `topical`
│   │   children:
│   │   ├── TextNode
│   │   │   full_match: `topical`
│   │   │   inner_content: `topical`
│   ├── TextNode
│   │   full_match: ` calcineurin inhibitors in pediatric patients with atopic dermatitis. BMC Pediatr. 2016;16:75.`
│   │   inner_content: ` calcineurin inhibitors in pediatric patients with atopic dermatitis. BMC Pediatr. 2016;16:75.`├── TextNode
│   full_match: `\n`
│   inner_content: `\n`├── NumListItemNode
│   full_match: `#Douglas WS, Poulin Y, Decroix J, et al. A new calcipotriol/betamethasone formulation with rapid onset of action was superior to monotherapy with betamethasone dipropionate or calcipotriol in psoriasis vulgaris. Acta Derm Venereol. 2002;82:131-135.`
│   inner_content: `Douglas WS, Poulin Y, Decroix J, et al. A new calcipotriol/betamethasone formulation with rapid onset of action was superior to monotherapy with betamethasone dipropionate or calcipotriol in psoriasis vulgaris. Acta Derm Venereol. 2002;82:131-135.`
│   depth: `1`
│   children:
│   ├── TextNode
│   │   full_match: `Douglas WS, Poulin Y, Decroix J, et al. A new calcipotriol/betamethasone formulation with rapid onset of action was superior to monotherapy with betamethasone dipropionate or calcipotriol in psoriasis vulgaris. Acta Derm Venereol. 2002;82:131-135.`
│   │   inner_content: `Douglas WS, Poulin Y, Decroix J, et al. A new calcipotriol/betamethasone formulation with rapid onset of action was superior to monotherapy with betamethasone dipropionate or calcipotriol in psoriasis vulgaris. Acta Derm Venereol. 2002;82:131-135.`├── TextNode
│   full_match: `\n`
│   inner_content: `\n`├── NumListItemNode
│   full_match: `#Papp KA, Guenther L, Boyden B, et al. Early onset of action and efficacy of a combination of calcipotriene and betamethasone dipropionate in the treatment of psoriasis. J Am Acad Dermatol. 2003;48:48-54.`
│   inner_content: `Papp KA, Guenther L, Boyden B, et al. Early onset of action and efficacy of a combination of calcipotriene and betamethasone dipropionate in the treatment of psoriasis. J Am Acad Dermatol. 2003;48:48-54.`
│   depth: `1`
│   children:
│   ├── TextNode
│   │   full_match: `Papp KA, Guenther L, Boyden B, et al. Early onset of action and efficacy of a combination of calcipotriene and betamethasone dipropionate in the treatment of psoriasis. J Am Acad Dermatol. 2003;48:48-54.`
│   │   inner_content: `Papp KA, Guenther L, Boyden B, et al. Early onset of action and efficacy of a combination of calcipotriene and betamethasone dipropionate in the treatment of psoriasis. J Am Acad Dermatol. 2003;48:48-54.`├── TextNode
│   full_match: `\n`
│   inner_content: `\n`├── NumListItemNode
│   full_match: `#Gottlieb AB, Ford RO, Spellman MC. The efficacy and tolerability of clobetasol propionate foam 0.05% in the treatment of mild to moderate plaque-type psoriasis of nonscalp regions. J Cutan Med Surg. 2003;7:185-192.`
│   inner_content: `Gottlieb AB, Ford RO, Spellman MC. The efficacy and tolerability of clobetasol propionate foam 0.05% in the treatment of mild to moderate plaque-type psoriasis of nonscalp regions. J Cutan Med Surg. 2003;7:185-192.`
│   depth: `1`
│   children:
│   ├── TextNode
│   │   full_match: `Gottlieb AB, Ford RO, Spellman MC. The efficacy and tolerability of clobetasol propionate foam 0.05% in the treatment of mild to moderate plaque-type psoriasis of nonscalp regions. J Cutan Med Surg. 2003;7:185-192.`
│   │   inner_content: `Gottlieb AB, Ford RO, Spellman MC. The efficacy and tolerability of clobetasol propionate foam 0.05% in the treatment of mild to moderate plaque-type psoriasis of nonscalp regions. J Cutan Med Surg. 2003;7:185-192.`├── TextNode
│   full_match: `\n`
│   inner_content: `\n`├── NumListItemNode
│   full_match: `#Weston WL, Fennessey PV, Morelli J, et al. Comparison of hypothalamus-pituitary-adrenal axis suppression from superpotent __topical steroids__ by standard endocrine function testing and gas chromatographic mass spectrometry. J Invest Dermatol. 1988;90:532-535.`
│   inner_content: `Weston WL, Fennessey PV, Morelli J, et al. Comparison of hypothalamus-pituitary-adrenal axis suppression from superpotent __topical steroids__ by standard endocrine function testing and gas chromatographic mass spectrometry. J Invest Dermatol. 1988;90:532-535.`
│   depth: `1`
│   children:
│   ├── TextNode
│   │   full_match: `Weston WL, Fennessey PV, Morelli J, et al. Comparison of hypothalamus-pituitary-adrenal axis suppression from superpotent `
│   │   inner_content: `Weston WL, Fennessey PV, Morelli J, et al. Comparison of hypothalamus-pituitary-adrenal axis suppression from superpotent `
│   ├── BoldNode
│   │   full_match: `__topical steroids__`
│   │   inner_content: `topical steroids`
│   │   children:
│   │   ├── TextNode
│   │   │   full_match: `topical steroids`
│   │   │   inner_content: `topical steroids`
│   ├── TextNode
│   │   full_match: ` by standard endocrine function testing and gas chromatographic mass spectrometry. J Invest Dermatol. 1988;90:532-535.`
│   │   inner_content: ` by standard endocrine function testing and gas chromatographic mass spectrometry. J Invest Dermatol. 1988;90:532-535.`├── TextNode
│   full_match: `\n`
│   inner_content: `\n`├── NumListItemNode
│   full_match: `#Wilsmann-Theis D, Gerdes S, Körber A, et al. Topische Therapie der Psoriasis.1. Auflage, Bremen: UNI-MED, 2016.`
│   inner_content: `Wilsmann-Theis D, Gerdes S, Körber A, et al. Topische Therapie der Psoriasis.1. Auflage, Bremen: UNI-MED, 2016.`
│   depth: `1`
│   children:
│   ├── TextNode
│   │   full_match: `Wilsmann-Theis D, Gerdes S, Körber A, et al. Topische Therapie der Psoriasis.1. Auflage, Bremen: UNI-MED, 2016.`
│   │   inner_content: `Wilsmann-Theis D, Gerdes S, Körber A, et al. Topische Therapie der Psoriasis.1. Auflage, Bremen: UNI-MED, 2016.`├── TextNode
│   full_match: `\n`
│   inner_content: `\n`├── NumListItemNode
│   full_match: `#Gerritsen MJ, Van De Kerkhof PC, Langner A. Long-term safety of __topical__ calcitriol 3 microg g(-1) ointment. Br J Dermatol. 2001;144(Suppl 58):17-19.`
│   inner_content: `Gerritsen MJ, Van De Kerkhof PC, Langner A. Long-term safety of __topical__ calcitriol 3 microg g(-1) ointment. Br J Dermatol. 2001;144(Suppl 58):17-19.`
│   depth: `1`
│   children:
│   ├── TextNode
│   │   full_match: `Gerritsen MJ, Van De Kerkhof PC, Langner A. Long-term safety of `
│   │   inner_content: `Gerritsen MJ, Van De Kerkhof PC, Langner A. Long-term safety of `
│   ├── BoldNode
│   │   full_match: `__topical__`
│   │   inner_content: `topical`
│   │   children:
│   │   ├── TextNode
│   │   │   full_match: `topical`
│   │   │   inner_content: `topical`
│   ├── TextNode
│   │   full_match: ` calcitriol 3 microg g(-1) ointment. Br J Dermatol. 2001;144(Suppl 58):17-19.`
│   │   inner_content: ` calcitriol 3 microg g(-1) ointment. Br J Dermatol. 2001;144(Suppl 58):17-19.`├── TextNode
│   full_match: `\n`
│   inner_content: `\n`├── NumListItemNode
│   full_match: `#Amichai B. Psoriasis of the glans penis in a child successfully treated with Elidel (pimecrolimus) cream. J Eur Acad Dermatol Venereol. 2004;18(6):742-743.`
│   inner_content: `Amichai B. Psoriasis of the glans penis in a child successfully treated with Elidel (pimecrolimus) cream. J Eur Acad Dermatol Venereol. 2004;18(6):742-743.`
│   depth: `1`
│   children:
│   ├── TextNode
│   │   full_match: `Amichai B. Psoriasis of the glans penis in a child successfully treated with Elidel (pimecrolimus) cream. J Eur Acad Dermatol Venereol. 2004;18(6):742-743.`
│   │   inner_content: `Amichai B. Psoriasis of the glans penis in a child successfully treated with Elidel (pimecrolimus) cream. J Eur Acad Dermatol Venereol. 2004;18(6):742-743.`├── TextNode
│   full_match: `\n`
│   inner_content: `\n`├── NumListItemNode
│   full_match: `#Freeman AK, Linowski GJ, Brady C, et al. Tacrolimus ointment for the treatment of psoriasis on the face and intertriginous areas. J Am Acad Dermatol. 2003;48(4):564-568.`
│   inner_content: `Freeman AK, Linowski GJ, Brady C, et al. Tacrolimus ointment for the treatment of psoriasis on the face and intertriginous areas. J Am Acad Dermatol. 2003;48(4):564-568.`
│   depth: `1`
│   children:
│   ├── TextNode
│   │   full_match: `Freeman AK, Linowski GJ, Brady C, et al. Tacrolimus ointment for the treatment of psoriasis on the face and intertriginous areas. J Am Acad Dermatol. 2003;48(4):564-568.`
│   │   inner_content: `Freeman AK, Linowski GJ, Brady C, et al. Tacrolimus ointment for the treatment of psoriasis on the face and intertriginous areas. J Am Acad Dermatol. 2003;48(4):564-568.`├── TextNode
│   full_match: `\n`
│   inner_content: `\n`├── NumListItemNode
│   full_match: `#Gribetz C, Ling M, Lebwohl M, et al. Pimecrolimus cream 1% in the treatment of intertriginous psoriasis: A double-blind, randomized study. J Am Acad Dermatol. 2004;51(5):731-738.`
│   inner_content: `Gribetz C, Ling M, Lebwohl M, et al. Pimecrolimus cream 1% in the treatment of intertriginous psoriasis: A double-blind, randomized study. J Am Acad Dermatol. 2004;51(5):731-738.`
│   depth: `1`
│   children:
│   ├── TextNode
│   │   full_match: `Gribetz C, Ling M, Lebwohl M, et al. Pimecrolimus cream 1% in the treatment of intertriginous psoriasis: A double-blind, randomized study. J Am Acad Dermatol. 2004;51(5):731-738.`
│   │   inner_content: `Gribetz C, Ling M, Lebwohl M, et al. Pimecrolimus cream 1% in the treatment of intertriginous psoriasis: A double-blind, randomized study. J Am Acad Dermatol. 2004;51(5):731-738.`├── TextNode
│   full_match: `\n`
│   inner_content: `\n`├── NumListItemNode
│   full_match: `#Remitz A, Reitamo S, Erkko P, et al. Tacrolimus ointment improves psoriasis in a microplaque assay. Br J Dermatol. 1999;141(1):103-107.`
│   inner_content: `Remitz A, Reitamo S, Erkko P, et al. Tacrolimus ointment improves psoriasis in a microplaque assay. Br J Dermatol. 1999;141(1):103-107.`
│   depth: `1`
│   children:
│   ├── TextNode
│   │   full_match: `Remitz A, Reitamo S, Erkko P, et al. Tacrolimus ointment improves psoriasis in a microplaque assay. Br J Dermatol. 1999;141(1):103-107.`
│   │   inner_content: `Remitz A, Reitamo S, Erkko P, et al. Tacrolimus ointment improves psoriasis in a microplaque assay. Br J Dermatol. 1999;141(1):103-107.`├── TextNode
│   full_match: `\n`
│   inner_content: `\n`├── NumListItemNode
│   full_match: `#Zonneveld IM, Rubins A, Jablonska S, et al. __topical__ tacrolimus is not effective in chronic plaque psoriasis. A pilot study. Arch Dermatol. 1998;134(9):1101-1102.`
│   inner_content: `Zonneveld IM, Rubins A, Jablonska S, et al. __topical__ tacrolimus is not effective in chronic plaque psoriasis. A pilot study. Arch Dermatol. 1998;134(9):1101-1102.`
│   depth: `1`
│   children:
│   ├── TextNode
│   │   full_match: `Zonneveld IM, Rubins A, Jablonska S, et al. `
│   │   inner_content: `Zonneveld IM, Rubins A, Jablonska S, et al. `
│   ├── BoldNode
│   │   full_match: `__topical__`
│   │   inner_content: `topical`
│   │   children:
│   │   ├── TextNode
│   │   │   full_match: `topical`
│   │   │   inner_content: `topical`
│   ├── TextNode
│   │   full_match: ` tacrolimus is not effective in chronic plaque psoriasis. A pilot study. Arch Dermatol. 1998;134(9):1101-1102.`
│   │   inner_content: ` tacrolimus is not effective in chronic plaque psoriasis. A pilot study. Arch Dermatol. 1998;134(9):1101-1102.`├── TextNode
│   full_match: `\n`
│   inner_content: `\n`├── NumListItemNode
│   full_match: `#Weischer M, Röcken M, Berneburg M. Calcineurin inhibitors and rapamycin: cancer protection or promotion? Exp Dermatol. 2007;16(5):385-393.`
│   inner_content: `Weischer M, Röcken M, Berneburg M. Calcineurin inhibitors and rapamycin: cancer protection or promotion? Exp Dermatol. 2007;16(5):385-393.`
│   depth: `1`
│   children:
│   ├── TextNode
│   │   full_match: `Weischer M, Röcken M, Berneburg M. Calcineurin inhibitors and rapamycin: cancer protection or promotion? Exp Dermatol. 2007;16(5):385-393.`
│   │   inner_content: `Weischer M, Röcken M, Berneburg M. Calcineurin inhibitors and rapamycin: cancer protection or promotion? Exp Dermatol. 2007;16(5):385-393.`├── TextNode
│   full_match: `\n`
│   inner_content: `\n`├── NumListItemNode
│   full_match: `#Reitamo S, Rissanen J, Remitz A, et al. Tacrolimus ointment does not affect collagen synthesis: results of a single-center randomized trial. J Invest Dermatol. 1998;111(3):396-398.`
│   inner_content: `Reitamo S, Rissanen J, Remitz A, et al. Tacrolimus ointment does not affect collagen synthesis: results of a single-center randomized trial. J Invest Dermatol. 1998;111(3):396-398.`
│   depth: `1`
│   children:
│   ├── TextNode
│   │   full_match: `Reitamo S, Rissanen J, Remitz A, et al. Tacrolimus ointment does not affect collagen synthesis: results of a single-center randomized trial. J Invest Dermatol. 1998;111(3):396-398.`
│   │   inner_content: `Reitamo S, Rissanen J, Remitz A, et al. Tacrolimus ointment does not affect collagen synthesis: results of a single-center randomized trial. J Invest Dermatol. 1998;111(3):396-398.`├── TextNode
│   full_match: `\n`
│   inner_content: `\n`├── NumListItemNode
│   full_match: `#Lebwohl M, Freeman AK, Chapman MS, et al. Tacrolimus ointment is effective for facial and intertriginous psoriasis. J Am Acad Dermatol. 2004;51(5):723-730.`
│   inner_content: `Lebwohl M, Freeman AK, Chapman MS, et al. Tacrolimus ointment is effective for facial and intertriginous psoriasis. J Am Acad Dermatol. 2004;51(5):723-730.`
│   depth: `1`
│   children:
│   ├── TextNode
│   │   full_match: `Lebwohl M, Freeman AK, Chapman MS, et al. Tacrolimus ointment is effective for facial and intertriginous psoriasis. J Am Acad Dermatol. 2004;51(5):723-730.`
│   │   inner_content: `Lebwohl M, Freeman AK, Chapman MS, et al. Tacrolimus ointment is effective for facial and intertriginous psoriasis. J Am Acad Dermatol. 2004;51(5):723-730.`├── TextNode
│   full_match: `\n`
│   inner_content: `\n`├── NumListItemNode
│   full_match: `#Doelker L, Tran C, Gkomouzas A, et al. Production and clearance of cyclobutane dipyrimidine dimers in UV-irradiated skin pretreated with 1% pimecrolimus or 0.1% triamcinolone acetonide creams in normal and atopic patients. Exp Dermatol. 2006;15:342-346.`
│   inner_content: `Doelker L, Tran C, Gkomouzas A, et al. Production and clearance of cyclobutane dipyrimidine dimers in UV-irradiated skin pretreated with 1% pimecrolimus or 0.1% triamcinolone acetonide creams in normal and atopic patients. Exp Dermatol. 2006;15:342-346.`
│   depth: `1`
│   children:
│   ├── TextNode
│   │   full_match: `Doelker L, Tran C, Gkomouzas A, et al. Production and clearance of cyclobutane dipyrimidine dimers in UV-irradiated skin pretreated with 1% pimecrolimus or 0.1% triamcinolone acetonide creams in normal and atopic patients. Exp Dermatol. 2006;15:342-346.`
│   │   inner_content: `Doelker L, Tran C, Gkomouzas A, et al. Production and clearance of cyclobutane dipyrimidine dimers in UV-irradiated skin pretreated with 1% pimecrolimus or 0.1% triamcinolone acetonide creams in normal and atopic patients. Exp Dermatol. 2006;15:342-346.`├── TextNode
│   full_match: `\n`
│   inner_content: `\n`├── NumListItemNode
│   full_match: `#Mrowietz U, Jessat H, Schwarz A, Schwarz T. Anthralin (dithranol) in vitro inhibits human monocytes to secrete IL-6, IL-8 and TNF-α, but not IL-1. Br J Dermatol. 1997;136(4):542-547.`
│   inner_content: `Mrowietz U, Jessat H, Schwarz A, Schwarz T. Anthralin (dithranol) in vitro inhibits human monocytes to secrete IL-6, IL-8 and TNF-α, but not IL-1. Br J Dermatol. 1997;136(4):542-547.`
│   depth: `1`
│   children:
│   ├── TextNode
│   │   full_match: `Mrowietz U, Jessat H, Schwarz A, Schwarz T. Anthralin (dithranol) in vitro inhibits human monocytes to secrete IL-6, IL-8 and TNF-α, but not IL-1. Br J Dermatol. 1997;136(4):542-547.`
│   │   inner_content: `Mrowietz U, Jessat H, Schwarz A, Schwarz T. Anthralin (dithranol) in vitro inhibits human monocytes to secrete IL-6, IL-8 and TNF-α, but not IL-1. Br J Dermatol. 1997;136(4):542-547.`├── TextNode
│   full_match: `\n`
│   inner_content: `\n`├── NumListItemNode
│   full_match: `#Painsi C, Patscheider M, Inzinger M, et al. Die Behandlung der Psoriasis mit klassischer, stationärer Dithranol-Therapie: eine retrospektive Patientenbefragung. J Dtsch Dermatol Ges. 2015;13(11):1156-1163.`
│   inner_content: `Painsi C, Patscheider M, Inzinger M, et al. Die Behandlung der Psoriasis mit klassischer, stationärer Dithranol-Therapie: eine retrospektive Patientenbefragung. J Dtsch Dermatol Ges. 2015;13(11):1156-1163.`
│   depth: `1`
│   children:
│   ├── TextNode
│   │   full_match: `Painsi C, Patscheider M, Inzinger M, et al. Die Behandlung der Psoriasis mit klassischer, stationärer Dithranol-Therapie: eine retrospektive Patientenbefragung. J Dtsch Dermatol Ges. 2015;13(11):1156-1163.`
│   │   inner_content: `Painsi C, Patscheider M, Inzinger M, et al. Die Behandlung der Psoriasis mit klassischer, stationärer Dithranol-Therapie: eine retrospektive Patientenbefragung. J Dtsch Dermatol Ges. 2015;13(11):1156-1163.`├── TextNode
│   full_match: `\n`
│   inner_content: `\n`├── NumListItemNode
│   full_match: `#Vtama (tapinarof) cream, for __topical__ use. US FDA approved product information; Long Beach, CA: Dermavant Sciences, Inc, 2022.`
│   inner_content: `Vtama (tapinarof) cream, for __topical__ use. US FDA approved product information; Long Beach, CA: Dermavant Sciences, Inc, 2022.`
│   depth: `1`
│   children:
│   ├── TextNode
│   │   full_match: `Vtama (tapinarof) cream, for `
│   │   inner_content: `Vtama (tapinarof) cream, for `
│   ├── BoldNode
│   │   full_match: `__topical__`
│   │   inner_content: `topical`
│   │   children:
│   │   ├── TextNode
│   │   │   full_match: `topical`
│   │   │   inner_content: `topical`
│   ├── TextNode
│   │   full_match: ` use. US FDA approved product information; Long Beach, CA: Dermavant Sciences, Inc, 2022.`
│   │   inner_content: ` use. US FDA approved product information; Long Beach, CA: Dermavant Sciences, Inc, 2022.`├── TextNode
│   full_match: `\n`
│   inner_content: `\n`├── NumListItemNode
│   full_match: `#Lebwohl MG, Stein Gold L, Strober B, et al. Phase 3 trials of tapinarof cream for plaque psoriasis. N Engl J Med. 2021;385:2219.`
│   inner_content: `Lebwohl MG, Stein Gold L, Strober B, et al. Phase 3 trials of tapinarof cream for plaque psoriasis. N Engl J Med. 2021;385:2219.`
│   depth: `1`
│   children:
│   ├── TextNode
│   │   full_match: `Lebwohl MG, Stein Gold L, Strober B, et al. Phase 3 trials of tapinarof cream for plaque psoriasis. N Engl J Med. 2021;385:2219.`
│   │   inner_content: `Lebwohl MG, Stein Gold L, Strober B, et al. Phase 3 trials of tapinarof cream for plaque psoriasis. N Engl J Med. 2021;385:2219.`├── TextNode
│   full_match: `\n`
│   inner_content: `\n`├── NumListItemNode
│   full_match: `#Lebwohl MG, Papp KA, Stein Gold L, et al. Trial of roflumilast cream for chronic plaque psoriasis. N Engl J Med. 2020;383(3):229-239.`
│   inner_content: `Lebwohl MG, Papp KA, Stein Gold L, et al. Trial of roflumilast cream for chronic plaque psoriasis. N Engl J Med. 2020;383(3):229-239.`
│   depth: `1`
│   children:
│   ├── TextNode
│   │   full_match: `Lebwohl MG, Papp KA, Stein Gold L, et al. Trial of roflumilast cream for chronic plaque psoriasis. N Engl J Med. 2020;383(3):229-239.`
│   │   inner_content: `Lebwohl MG, Papp KA, Stein Gold L, et al. Trial of roflumilast cream for chronic plaque psoriasis. N Engl J Med. 2020;383(3):229-239.`├── TextNode
│   full_match: `\n`
│   inner_content: `\n`├── NumListItemNode
│   full_match: `#Körber A, Wilsmann-Theis D, Augustun M, et al. Topische Therapie bei Psoriasis vulgaris - ein Behandlungspfad. J Dtsch Dermatol Ges. 2019;17(Suppl 4):3-14.`
│   inner_content: `Körber A, Wilsmann-Theis D, Augustun M, et al. Topische Therapie bei Psoriasis vulgaris - ein Behandlungspfad. J Dtsch Dermatol Ges. 2019;17(Suppl 4):3-14.`
│   depth: `1`
│   children:
│   ├── TextNode
│   │   full_match: `Körber A, Wilsmann-Theis D, Augustun M, et al. Topische Therapie bei Psoriasis vulgaris - ein Behandlungspfad. J Dtsch Dermatol Ges. 2019;17(Suppl 4):3-14.`
│   │   inner_content: `Körber A, Wilsmann-Theis D, Augustun M, et al. Topische Therapie bei Psoriasis vulgaris - ein Behandlungspfad. J Dtsch Dermatol Ges. 2019;17(Suppl 4):3-14.`├── TextNode
│   full_match: `\n`
│   inner_content: `\n`├── NumListItemNode
│   full_match: `#Ruzicka T, Lorenz B. Comparison of calcipotriol monotherapy and a combination of calcipotriol and betamethasone valerate after 2 weeks’ treatment with calcipotriol in the __topical__ therapy of psoriasis vulgaris: a multicentre, double-blind, randomized study. Br J Dermatol. 1998;138(2):254-258.`
│   inner_content: `Ruzicka T, Lorenz B. Comparison of calcipotriol monotherapy and a combination of calcipotriol and betamethasone valerate after 2 weeks’ treatment with calcipotriol in the __topical__ therapy of psoriasis vulgaris: a multicentre, double-blind, randomized study. Br J Dermatol. 1998;138(2):254-258.`
│   depth: `1`
│   children:
│   ├── TextNode
│   │   full_match: `Ruzicka T, Lorenz B. Comparison of calcipotriol monotherapy and a combination of calcipotriol and betamethasone valerate after 2 weeks’ treatment with calcipotriol in the `
│   │   inner_content: `Ruzicka T, Lorenz B. Comparison of calcipotriol monotherapy and a combination of calcipotriol and betamethasone valerate after 2 weeks’ treatment with calcipotriol in the `
│   ├── BoldNode
│   │   full_match: `__topical__`
│   │   inner_content: `topical`
│   │   children:
│   │   ├── TextNode
│   │   │   full_match: `topical`
│   │   │   inner_content: `topical`
│   ├── TextNode
│   │   full_match: ` therapy of psoriasis vulgaris: a multicentre, double-blind, randomized study. Br J Dermatol. 1998;138(2):254-258.`
│   │   inner_content: ` therapy of psoriasis vulgaris: a multicentre, double-blind, randomized study. Br J Dermatol. 1998;138(2):254-258.`├── TextNode
│   full_match: `\n`
│   inner_content: `\n`├── NumListItemNode
│   full_match: `#Kragballe K, Barnes L, Hamberg KJ, et al. Calcipotriol cream with or without concurrent __topical corticosteroid__ in psoriasis: tolerability and efficacy. Br J Dermatol. 1998;139(4):649-654.`
│   inner_content: `Kragballe K, Barnes L, Hamberg KJ, et al. Calcipotriol cream with or without concurrent __topical corticosteroid__ in psoriasis: tolerability and efficacy. Br J Dermatol. 1998;139(4):649-654.`
│   depth: `1`
│   children:
│   ├── TextNode
│   │   full_match: `Kragballe K, Barnes L, Hamberg KJ, et al. Calcipotriol cream with or without concurrent `
│   │   inner_content: `Kragballe K, Barnes L, Hamberg KJ, et al. Calcipotriol cream with or without concurrent `
│   ├── BoldNode
│   │   full_match: `__topical corticosteroid__`
│   │   inner_content: `topical corticosteroid`
│   │   children:
│   │   ├── TextNode
│   │   │   full_match: `topical corticosteroid`
│   │   │   inner_content: `topical corticosteroid`
│   ├── TextNode
│   │   full_match: ` in psoriasis: tolerability and efficacy. Br J Dermatol. 1998;139(4):649-654.`
│   │   inner_content: ` in psoriasis: tolerability and efficacy. Br J Dermatol. 1998;139(4):649-654.`├── TextNode
│   full_match: `\n`
│   inner_content: `\n`├── NumListItemNode
│   full_match: `#Radtke MA, Herberger K, Kornek T, Augustin M. [Calcipotriol plus betamethasone dipropionate gel in the treatment of scalp psoriasis. A review]. Hautarzt. 2010;61(9):770-775.`
│   inner_content: `Radtke MA, Herberger K, Kornek T, Augustin M. [Calcipotriol plus betamethasone dipropionate gel in the treatment of scalp psoriasis. A review]. Hautarzt. 2010;61(9):770-775.`
│   depth: `1`
│   children:
│   ├── TextNode
│   │   full_match: `Radtke MA, Herberger K, Kornek T, Augustin M. `
│   │   inner_content: `Radtke MA, Herberger K, Kornek T, Augustin M. `
│   ├── LinkNode
│   │   full_match: `[Calcipotriol plus betamethasone dipropionate gel in the treatment of scalp psoriasis. A review]`
│   │   inner_content: `Calcipotriol plus betamethasone dipropionate gel in the treatment of scalp psoriasis. A review`
│   │   url: `Calcipotriol plus betamethasone dipropionate gel in the treatment of scalp psoriasis. A review`
│   │   children:
│   │   ├── TextNode
│   │   │   full_match: `Calcipotriol plus betamethasone dipropionate gel in the treatment of scalp psoriasis. A review`
│   │   │   inner_content: `Calcipotriol plus betamethasone dipropionate gel in the treatment of scalp psoriasis. A review`
│   ├── TextNode
│   │   full_match: `. Hautarzt. 2010;61(9):770-775.`
│   │   inner_content: `. Hautarzt. 2010;61(9):770-775.`├── TextNode
│   full_match: `\n`
│   inner_content: `\n`├── NumListItemNode
│   full_match: `#Leonardi C, Bagel J, Yamauchi P, Pariser D, et al. Efficacy and safety of calcipotriene plus betamethasone dipropionate aerosol foam in patients with psoriasis vulgaris - a randomized phase III study (PSO-FAST). J Drugs Dermatol. 2015;14(12):1468-1477.`
│   inner_content: `Leonardi C, Bagel J, Yamauchi P, Pariser D, et al. Efficacy and safety of calcipotriene plus betamethasone dipropionate aerosol foam in patients with psoriasis vulgaris - a randomized phase III study (PSO-FAST). J Drugs Dermatol. 2015;14(12):1468-1477.`
│   depth: `1`
│   children:
│   ├── TextNode
│   │   full_match: `Leonardi C, Bagel J, Yamauchi P, Pariser D, et al. Efficacy and safety of calcipotriene plus betamethasone dipropionate aerosol foam in patients with psoriasis vulgaris - a randomized phase III study (PSO-FAST). J Drugs Dermatol. 2015;14(12):1468-1477.`
│   │   inner_content: `Leonardi C, Bagel J, Yamauchi P, Pariser D, et al. Efficacy and safety of calcipotriene plus betamethasone dipropionate aerosol foam in patients with psoriasis vulgaris - a randomized phase III study (PSO-FAST). J Drugs Dermatol. 2015;14(12):1468-1477.`├── TextNode
│   full_match: `\n`
│   inner_content: `\n`├── NumListItemNode
│   full_match: `#Lebwohl M, Tyring S, Bukhalo M, et al. Fixed combination aerosol foam calcipotriene 0.005% (cal) plus betamethasone dipropionate0.064% (bd) is more efficacious than Cal or BD aerosol foam alone for psoriasis vulgaris: a randomized, double-blind, multicenter, three-arm, phase 2 study. J Clin Aesthet Dermatol. 2016;9(2):34.`
│   inner_content: `Lebwohl M, Tyring S, Bukhalo M, et al. Fixed combination aerosol foam calcipotriene 0.005% (cal) plus betamethasone dipropionate0.064% (bd) is more efficacious than Cal or BD aerosol foam alone for psoriasis vulgaris: a randomized, double-blind, multicenter, three-arm, phase 2 study. J Clin Aesthet Dermatol. 2016;9(2):34.`
│   depth: `1`
│   children:
│   ├── TextNode
│   │   full_match: `Lebwohl M, Tyring S, Bukhalo M, et al. Fixed combination aerosol foam calcipotriene 0.005% (cal) plus betamethasone dipropionate0.064% (bd) is more efficacious than Cal or BD aerosol foam alone for psoriasis vulgaris: a randomized, double-blind, multicenter, three-arm, phase 2 study. J Clin Aesthet Dermatol. 2016;9(2):34.`
│   │   inner_content: `Lebwohl M, Tyring S, Bukhalo M, et al. Fixed combination aerosol foam calcipotriene 0.005% (cal) plus betamethasone dipropionate0.064% (bd) is more efficacious than Cal or BD aerosol foam alone for psoriasis vulgaris: a randomized, double-blind, multicenter, three-arm, phase 2 study. J Clin Aesthet Dermatol. 2016;9(2):34.`├── TextNode
│   full_match: `\n`
│   inner_content: `\n`├── NumListItemNode
│   full_match: `#Koo J, Tyring S, Werschler WP, et al. Superior efficacy of calcipotriene and betamethasone dipropionate aerosol foam versus ointment in patients with psoriasis vulgaris - A randomized phase II study. J Dermatolog Treat. 2016;27(2):120-127.`
│   inner_content: `Koo J, Tyring S, Werschler WP, et al. Superior efficacy of calcipotriene and betamethasone dipropionate aerosol foam versus ointment in patients with psoriasis vulgaris - A randomized phase II study. J Dermatolog Treat. 2016;27(2):120-127.`
│   depth: `1`
│   children:
│   ├── TextNode
│   │   full_match: `Koo J, Tyring S, Werschler WP, et al. Superior efficacy of calcipotriene and betamethasone dipropionate aerosol foam versus ointment in patients with psoriasis vulgaris - A randomized phase II study. J Dermatolog Treat. 2016;27(2):120-127.`
│   │   inner_content: `Koo J, Tyring S, Werschler WP, et al. Superior efficacy of calcipotriene and betamethasone dipropionate aerosol foam versus ointment in patients with psoriasis vulgaris - A randomized phase II study. J Dermatolog Treat. 2016;27(2):120-127.`├── TextNode
│   full_match: `\n`
│   inner_content: `\n`├── NumListItemNode
│   full_match: `#Paul C, Stein Gold L, Cambazard F, et al. Calcipotriol plus betamethasone dipropionate aerosol foam provides superior efficacy vs. gel in patients with psoriasis vulgaris: randomized, controlled PSO-ABLE study. J Eur Acad Dermatol Venereol. 2017;31(1):119-126.`
│   inner_content: `Paul C, Stein Gold L, Cambazard F, et al. Calcipotriol plus betamethasone dipropionate aerosol foam provides superior efficacy vs. gel in patients with psoriasis vulgaris: randomized, controlled PSO-ABLE study. J Eur Acad Dermatol Venereol. 2017;31(1):119-126.`
│   depth: `1`
│   children:
│   ├── TextNode
│   │   full_match: `Paul C, Stein Gold L, Cambazard F, et al. Calcipotriol plus betamethasone dipropionate aerosol foam provides superior efficacy vs. gel in patients with psoriasis vulgaris: randomized, controlled PSO-ABLE study. J Eur Acad Dermatol Venereol. 2017;31(1):119-126.`
│   │   inner_content: `Paul C, Stein Gold L, Cambazard F, et al. Calcipotriol plus betamethasone dipropionate aerosol foam provides superior efficacy vs. gel in patients with psoriasis vulgaris: randomized, controlled PSO-ABLE study. J Eur Acad Dermatol Venereol. 2017;31(1):119-126.`├── TextNode
│   full_match: `\n`
│   inner_content: `\n`├── NumListItemNode
│   full_match: `#Lind M, Nielsen KT, Schefe LH, et al. Supersaturation of calcipotriene and betamethasone dipropionate in a novel aerosol foam formulation for __topical__ treatment of psoriasis provides enhanced bioavailability of the active ingredients. Dermatol Ther (Heidelb). 2016;6(3):413-425.`
│   inner_content: `Lind M, Nielsen KT, Schefe LH, et al. Supersaturation of calcipotriene and betamethasone dipropionate in a novel aerosol foam formulation for __topical__ treatment of psoriasis provides enhanced bioavailability of the active ingredients. Dermatol Ther (Heidelb). 2016;6(3):413-425.`
│   depth: `1`
│   children:
│   ├── TextNode
│   │   full_match: `Lind M, Nielsen KT, Schefe LH, et al. Supersaturation of calcipotriene and betamethasone dipropionate in a novel aerosol foam formulation for `
│   │   inner_content: `Lind M, Nielsen KT, Schefe LH, et al. Supersaturation of calcipotriene and betamethasone dipropionate in a novel aerosol foam formulation for `
│   ├── BoldNode
│   │   full_match: `__topical__`
│   │   inner_content: `topical`
│   │   children:
│   │   ├── TextNode
│   │   │   full_match: `topical`
│   │   │   inner_content: `topical`
│   ├── TextNode
│   │   full_match: ` treatment of psoriasis provides enhanced bioavailability of the active ingredients. Dermatol Ther (Heidelb). 2016;6(3):413-425.`
│   │   inner_content: ` treatment of psoriasis provides enhanced bioavailability of the active ingredients. Dermatol Ther (Heidelb). 2016;6(3):413-425.`├── TextNode
│   full_match: `\n`
│   inner_content: `\n`├── NumListItemNode
│   full_match: `#Samarasekera EJ, Sawyer L, Wonderling D, et al. __topical__ therapies for the treatment of plaque psoriasis: systematic review and network metaanalyses. Br J Dermatol. 2013;168(5):954-967.`
│   inner_content: `Samarasekera EJ, Sawyer L, Wonderling D, et al. __topical__ therapies for the treatment of plaque psoriasis: systematic review and network metaanalyses. Br J Dermatol. 2013;168(5):954-967.`
│   depth: `1`
│   children:
│   ├── TextNode
│   │   full_match: `Samarasekera EJ, Sawyer L, Wonderling D, et al. `
│   │   inner_content: `Samarasekera EJ, Sawyer L, Wonderling D, et al. `
│   ├── BoldNode
│   │   full_match: `__topical__`
│   │   inner_content: `topical`
│   │   children:
│   │   ├── TextNode
│   │   │   full_match: `topical`
│   │   │   inner_content: `topical`
│   ├── TextNode
│   │   full_match: ` therapies for the treatment of plaque psoriasis: systematic review and network metaanalyses. Br J Dermatol. 2013;168(5):954-967.`
│   │   inner_content: ` therapies for the treatment of plaque psoriasis: systematic review and network metaanalyses. Br J Dermatol. 2013;168(5):954-967.`├── TextNode
│   full_match: `\n`
│   inner_content: `\n`├── NumListItemNode
│   full_match: `#Mason AR, Mason J, Cork M, et al. __topical__ treatments for chronic plaque psoriasis. Cochrane database Syst Rev. 2009;(2):CD005028.`
│   inner_content: `Mason AR, Mason J, Cork M, et al. __topical__ treatments for chronic plaque psoriasis. Cochrane database Syst Rev. 2009;(2):CD005028.`
│   depth: `1`
│   children:
│   ├── TextNode
│   │   full_match: `Mason AR, Mason J, Cork M, et al. `
│   │   inner_content: `Mason AR, Mason J, Cork M, et al. `
│   ├── BoldNode
│   │   full_match: `__topical__`
│   │   inner_content: `topical`
│   │   children:
│   │   ├── TextNode
│   │   │   full_match: `topical`
│   │   │   inner_content: `topical`
│   ├── TextNode
│   │   full_match: ` treatments for chronic plaque psoriasis. Cochrane database Syst Rev. 2009;(2):CD005028.`
│   │   inner_content: ` treatments for chronic plaque psoriasis. Cochrane database Syst Rev. 2009;(2):CD005028.`├── TextNode
│   full_match: `\n`
│   inner_content: `\n`├── NumListItemNode
│   full_match: `#Saraceno R, Camplone G, D&#39;Agostino M, et al. Efficacy and maintenance strategies of two-compound formulation calcipotriol and betamethasone dipropionate gel (Xamiol® gel) in the treatment of scalp psoriasis: results from a study in 885 patients. J Dermatolog Treat. 2014;25(1):30-33.`
│   inner_content: `Saraceno R, Camplone G, D&#39;Agostino M, et al. Efficacy and maintenance strategies of two-compound formulation calcipotriol and betamethasone dipropionate gel (Xamiol® gel) in the treatment of scalp psoriasis: results from a study in 885 patients. J Dermatolog Treat. 2014;25(1):30-33.`
│   depth: `1`
│   children:
│   ├── TextNode
│   │   full_match: `Saraceno R, Camplone G, D&#39;Agostino M, et al. Efficacy and maintenance strategies of two-compound formulation calcipotriol and betamethasone dipropionate gel (Xamiol® gel) in the treatment of scalp psoriasis: results from a study in 885 patients. J Dermatolog Treat. 2014;25(1):30-33.`
│   │   inner_content: `Saraceno R, Camplone G, D&#39;Agostino M, et al. Efficacy and maintenance strategies of two-compound formulation calcipotriol and betamethasone dipropionate gel (Xamiol® gel) in the treatment of scalp psoriasis: results from a study in 885 patients. J Dermatolog Treat. 2014;25(1):30-33.`├── TextNode
│   full_match: `\n`
│   inner_content: `\n`├── NumListItemNode
│   full_match: `#Stein Gold L, Alonso-Llamazares J, Lacour JP, et al. PSO-LONG: Design of a novel, 12-month clinical trial of __topical__, proactive maintenance with twice-weekly Cal/BD foam in psoriasis. Adv Ther. 2020;37(11):4730-4753.`
│   inner_content: `Stein Gold L, Alonso-Llamazares J, Lacour JP, et al. PSO-LONG: Design of a novel, 12-month clinical trial of __topical__, proactive maintenance with twice-weekly Cal/BD foam in psoriasis. Adv Ther. 2020;37(11):4730-4753.`
│   depth: `1`
│   children:
│   ├── TextNode
│   │   full_match: `Stein Gold L, Alonso-Llamazares J, Lacour JP, et al. PSO-LONG: Design of a novel, 12-month clinical trial of `
│   │   inner_content: `Stein Gold L, Alonso-Llamazares J, Lacour JP, et al. PSO-LONG: Design of a novel, 12-month clinical trial of `
│   ├── BoldNode
│   │   full_match: `__topical__`
│   │   inner_content: `topical`
│   │   children:
│   │   ├── TextNode
│   │   │   full_match: `topical`
│   │   │   inner_content: `topical`
│   ├── TextNode
│   │   full_match: `, proactive maintenance with twice-weekly Cal/BD foam in psoriasis. Adv Ther. 2020;37(11):4730-4753.`
│   │   inner_content: `, proactive maintenance with twice-weekly Cal/BD foam in psoriasis. Adv Ther. 2020;37(11):4730-4753.`├── TextNode
│   full_match: `\n`
│   inner_content: `\n`├── NumListItemNode
│   full_match: `#van de Kerkhof PC, de Hoop D, de Korte J, Kuipers MV. Scalp psoriasis, clinical presentations and therapeutic management. Dermatology. 1998;197(4):326-334.`
│   inner_content: `van de Kerkhof PC, de Hoop D, de Korte J, Kuipers MV. Scalp psoriasis, clinical presentations and therapeutic management. Dermatology. 1998;197(4):326-334.`
│   depth: `1`
│   children:
│   ├── TextNode
│   │   full_match: `van de Kerkhof PC, de Hoop D, de Korte J, Kuipers MV. Scalp psoriasis, clinical presentations and therapeutic management. Dermatology. 1998;197(4):326-334.`
│   │   inner_content: `van de Kerkhof PC, de Hoop D, de Korte J, Kuipers MV. Scalp psoriasis, clinical presentations and therapeutic management. Dermatology. 1998;197(4):326-334.`├── TextNode
│   full_match: `\n`
│   inner_content: `\n`├── NumListItemNode
│   full_match: `#Schlager JG, Rosumeck S, Werner RN, et al. __topical__ treatments for scalp psoriasis: summary of a Cochrane Systematic Review. Br J Dermatol. 2017;176(3):604-614.`
│   inner_content: `Schlager JG, Rosumeck S, Werner RN, et al. __topical__ treatments for scalp psoriasis: summary of a Cochrane Systematic Review. Br J Dermatol. 2017;176(3):604-614.`
│   depth: `1`
│   children:
│   ├── TextNode
│   │   full_match: `Schlager JG, Rosumeck S, Werner RN, et al. `
│   │   inner_content: `Schlager JG, Rosumeck S, Werner RN, et al. `
│   ├── BoldNode
│   │   full_match: `__topical__`
│   │   inner_content: `topical`
│   │   children:
│   │   ├── TextNode
│   │   │   full_match: `topical`
│   │   │   inner_content: `topical`
│   ├── TextNode
│   │   full_match: ` treatments for scalp psoriasis: summary of a Cochrane Systematic Review. Br J Dermatol. 2017;176(3):604-614.`
│   │   inner_content: ` treatments for scalp psoriasis: summary of a Cochrane Systematic Review. Br J Dermatol. 2017;176(3):604-614.`├── TextNode
│   full_match: `\n`
│   inner_content: `\n`├── NumListItemNode
│   full_match: `#Schlager JG, Rosumeck S, Werner RN, et al. __topical__ treatments for scalp psoriasis. Vol. 2016, Cochrane Database of Systematic Reviews. John Wiley and Sons Ltd. 2016;2:CD009687.`
│   inner_content: `Schlager JG, Rosumeck S, Werner RN, et al. __topical__ treatments for scalp psoriasis. Vol. 2016, Cochrane Database of Systematic Reviews. John Wiley and Sons Ltd. 2016;2:CD009687.`
│   depth: `1`
│   children:
│   ├── TextNode
│   │   full_match: `Schlager JG, Rosumeck S, Werner RN, et al. `
│   │   inner_content: `Schlager JG, Rosumeck S, Werner RN, et al. `
│   ├── BoldNode
│   │   full_match: `__topical__`
│   │   inner_content: `topical`
│   │   children:
│   │   ├── TextNode
│   │   │   full_match: `topical`
│   │   │   inner_content: `topical`
│   ├── TextNode
│   │   full_match: ` treatments for scalp psoriasis. Vol. 2016, Cochrane Database of Systematic Reviews. John Wiley and Sons Ltd. 2016;2:CD009687.`
│   │   inner_content: ` treatments for scalp psoriasis. Vol. 2016, Cochrane Database of Systematic Reviews. John Wiley and Sons Ltd. 2016;2:CD009687.`├── TextNode
│   full_match: `\n`
│   inner_content: `\n`├── NumListItemNode
│   full_match: `#Chan CS, Van Voorhees AS, Lebwohl MG, et al. Treatment of severe scalp psoriasis: From the Medical Board of the National Psoriasis Foundation. J Am Acad Dermatol. 2009;60(6):962-971.`
│   inner_content: `Chan CS, Van Voorhees AS, Lebwohl MG, et al. Treatment of severe scalp psoriasis: From the Medical Board of the National Psoriasis Foundation. J Am Acad Dermatol. 2009;60(6):962-971.`
│   depth: `1`
│   children:
│   ├── TextNode
│   │   full_match: `Chan CS, Van Voorhees AS, Lebwohl MG, et al. Treatment of severe scalp psoriasis: From the Medical Board of the National Psoriasis Foundation. J Am Acad Dermatol. 2009;60(6):962-971.`
│   │   inner_content: `Chan CS, Van Voorhees AS, Lebwohl MG, et al. Treatment of severe scalp psoriasis: From the Medical Board of the National Psoriasis Foundation. J Am Acad Dermatol. 2009;60(6):962-971.`├── TextNode
│   full_match: `\n`
│   inner_content: `\n`├── NumListItemNode
│   full_match: `#Jacobi A, Braeutigam M, Mahler V, et al. Pimecrolimus 1% cream in the treatment of facial psoriasis: A 16-week open-label study. Dermatology. 2008;216(2):133-136.`
│   inner_content: `Jacobi A, Braeutigam M, Mahler V, et al. Pimecrolimus 1% cream in the treatment of facial psoriasis: A 16-week open-label study. Dermatology. 2008;216(2):133-136.`
│   depth: `1`
│   children:
│   ├── TextNode
│   │   full_match: `Jacobi A, Braeutigam M, Mahler V, et al. Pimecrolimus 1% cream in the treatment of facial psoriasis: A 16-week open-label study. Dermatology. 2008;216(2):133-136.`
│   │   inner_content: `Jacobi A, Braeutigam M, Mahler V, et al. Pimecrolimus 1% cream in the treatment of facial psoriasis: A 16-week open-label study. Dermatology. 2008;216(2):133-136.`├── TextNode
│   full_match: `\n`
│   inner_content: `\n`├── NumListItemNode
│   full_match: `#Jiaravuthisan MM, Sasseville D, Vender RB, et al. Psoriasis of the nail: Anatomy, pathology, clinical presentation, and a review of the literature on therapy. J Am Acad Dermatol. 2007;57(1):1-27.`
│   inner_content: `Jiaravuthisan MM, Sasseville D, Vender RB, et al. Psoriasis of the nail: Anatomy, pathology, clinical presentation, and a review of the literature on therapy. J Am Acad Dermatol. 2007;57(1):1-27.`
│   depth: `1`
│   children:
│   ├── TextNode
│   │   full_match: `Jiaravuthisan MM, Sasseville D, Vender RB, et al. Psoriasis of the nail: Anatomy, pathology, clinical presentation, and a review of the literature on therapy. J Am Acad Dermatol. 2007;57(1):1-27.`
│   │   inner_content: `Jiaravuthisan MM, Sasseville D, Vender RB, et al. Psoriasis of the nail: Anatomy, pathology, clinical presentation, and a review of the literature on therapy. J Am Acad Dermatol. 2007;57(1):1-27.`├── TextNode
│   full_match: `\n`
│   inner_content: `\n`├── NumListItemNode
│   full_match: `#Williamson L, Dalbeth N, Dockerty JL, et al. Extended report: nail disease in psoriatic arthritis - clinically important, potentially treatable and often overlooked. Rheumatology (Oxford). 2004;43(6):790-794.`
│   inner_content: `Williamson L, Dalbeth N, Dockerty JL, et al. Extended report: nail disease in psoriatic arthritis - clinically important, potentially treatable and often overlooked. Rheumatology (Oxford). 2004;43(6):790-794.`
│   depth: `1`
│   children:
│   ├── TextNode
│   │   full_match: `Williamson L, Dalbeth N, Dockerty JL, et al. Extended report: nail disease in psoriatic arthritis - clinically important, potentially treatable and often overlooked. Rheumatology (Oxford). 2004;43(6):790-794.`
│   │   inner_content: `Williamson L, Dalbeth N, Dockerty JL, et al. Extended report: nail disease in psoriatic arthritis - clinically important, potentially treatable and often overlooked. Rheumatology (Oxford). 2004;43(6):790-794.`├── TextNode
│   full_match: `\n`
│   inner_content: `\n`├── NumListItemNode
│   full_match: `#De Berker D. Management of psoriatic nail disease. Semin Cutan Med Surg. 2009;28(1):39-43.`
│   inner_content: `De Berker D. Management of psoriatic nail disease. Semin Cutan Med Surg. 2009;28(1):39-43.`
│   depth: `1`
│   children:
│   ├── TextNode
│   │   full_match: `De Berker D. Management of psoriatic nail disease. Semin Cutan Med Surg. 2009;28(1):39-43.`
│   │   inner_content: `De Berker D. Management of psoriatic nail disease. Semin Cutan Med Surg. 2009;28(1):39-43.`├── TextNode
│   full_match: `\n`
│   inner_content: `\n`├── NumListItemNode
│   full_match: `#Pasch MC. Nail Psoriasis: A review of treatment options. Drugs. 2016;76(6):675-705.`
│   inner_content: `Pasch MC. Nail Psoriasis: A review of treatment options. Drugs. 2016;76(6):675-705.`
│   depth: `1`
│   children:
│   ├── TextNode
│   │   full_match: `Pasch MC. Nail Psoriasis: A review of treatment options. Drugs. 2016;76(6):675-705.`
│   │   inner_content: `Pasch MC. Nail Psoriasis: A review of treatment options. Drugs. 2016;76(6):675-705.`├── TextNode
│   full_match: `\n`
│   inner_content: `\n`├── NumListItemNode
│   full_match: `#Rigopoulos D, Gregoriou S, Daniel Iii CR, et al. Treatment of nail psoriasis with a two-compound formulation of calcipotriol plus betamethasone dipropionate ointment. Dermatology. 2009;218(4):338-341.`
│   inner_content: `Rigopoulos D, Gregoriou S, Daniel Iii CR, et al. Treatment of nail psoriasis with a two-compound formulation of calcipotriol plus betamethasone dipropionate ointment. Dermatology. 2009;218(4):338-341.`
│   depth: `1`
│   children:
│   ├── TextNode
│   │   full_match: `Rigopoulos D, Gregoriou S, Daniel Iii CR, et al. Treatment of nail psoriasis with a two-compound formulation of calcipotriol plus betamethasone dipropionate ointment. Dermatology. 2009;218(4):338-341.`
│   │   inner_content: `Rigopoulos D, Gregoriou S, Daniel Iii CR, et al. Treatment of nail psoriasis with a two-compound formulation of calcipotriol plus betamethasone dipropionate ointment. Dermatology. 2009;218(4):338-341.`├── TextNode
│   full_match: `\n`
│   inner_content: `\n`├── NumListItemNode
│   full_match: `#Rigopoulos D, Ioannides D, Prastitis N, Katsambas A. Nail psoriasis: a combined treatment using calcipotriol cream and clobetasol propionate cream. Acta Derm Venereol. 2002;82(2):140.`
│   inner_content: `Rigopoulos D, Ioannides D, Prastitis N, Katsambas A. Nail psoriasis: a combined treatment using calcipotriol cream and clobetasol propionate cream. Acta Derm Venereol. 2002;82(2):140.`
│   depth: `1`
│   children:
│   ├── TextNode
│   │   full_match: `Rigopoulos D, Ioannides D, Prastitis N, Katsambas A. Nail psoriasis: a combined treatment using calcipotriol cream and clobetasol propionate cream. Acta Derm Venereol. 2002;82(2):140.`
│   │   inner_content: `Rigopoulos D, Ioannides D, Prastitis N, Katsambas A. Nail psoriasis: a combined treatment using calcipotriol cream and clobetasol propionate cream. Acta Derm Venereol. 2002;82(2):140.`├── TextNode
│   full_match: `\n`
│   inner_content: `\n`├── NumListItemNode
│   full_match: `#Tzung TY, Chen CY, Yang CY, et al. Calcipotriol used as monotherapy or combination therapy with betamethasone dipropionate in the treatment of nail psoriasis. Acta Derm Venereol. 2008;88(3):279-280.`
│   inner_content: `Tzung TY, Chen CY, Yang CY, et al. Calcipotriol used as monotherapy or combination therapy with betamethasone dipropionate in the treatment of nail psoriasis. Acta Derm Venereol. 2008;88(3):279-280.`
│   depth: `1`
│   children:
│   ├── TextNode
│   │   full_match: `Tzung TY, Chen CY, Yang CY, et al. Calcipotriol used as monotherapy or combination therapy with betamethasone dipropionate in the treatment of nail psoriasis. Acta Derm Venereol. 2008;88(3):279-280.`
│   │   inner_content: `Tzung TY, Chen CY, Yang CY, et al. Calcipotriol used as monotherapy or combination therapy with betamethasone dipropionate in the treatment of nail psoriasis. Acta Derm Venereol. 2008;88(3):279-280.`├── TextNode
│   full_match: `\n`
│   inner_content: `\n`├── NumListItemNode
│   full_match: `#Chi CC, Wang SH, Mayon-White R, Wojnarowska F. Pregnancy outcomes after maternal exposure to __topical corticosteroids__: a UK population-based cohort study. JAMA dermatology. 2013;149(11):1274-1280.`
│   inner_content: `Chi CC, Wang SH, Mayon-White R, Wojnarowska F. Pregnancy outcomes after maternal exposure to __topical corticosteroids__: a UK population-based cohort study. JAMA dermatology. 2013;149(11):1274-1280.`
│   depth: `1`
│   children:
│   ├── TextNode
│   │   full_match: `Chi CC, Wang SH, Mayon-White R, Wojnarowska F. Pregnancy outcomes after maternal exposure to `
│   │   inner_content: `Chi CC, Wang SH, Mayon-White R, Wojnarowska F. Pregnancy outcomes after maternal exposure to `
│   ├── BoldNode
│   │   full_match: `__topical corticosteroids__`
│   │   inner_content: `topical corticosteroids`
│   │   children:
│   │   ├── TextNode
│   │   │   full_match: `topical corticosteroids`
│   │   │   inner_content: `topical corticosteroids`
│   ├── TextNode
│   │   full_match: `: a UK population-based cohort study. JAMA dermatology. 2013;149(11):1274-1280.`
│   │   inner_content: `: a UK population-based cohort study. JAMA dermatology. 2013;149(11):1274-1280.`├── TextNode
│   full_match: `\n`
│   inner_content: `\n`├── NumListItemNode
│   full_match: `#Gottlieb AB, Ryan C, Murase JE. Clinical considerations for the management of psoriasis in women. Int J women&#39;s dermatology. 2019;5(3):141-150.`
│   inner_content: `Gottlieb AB, Ryan C, Murase JE. Clinical considerations for the management of psoriasis in women. Int J women&#39;s dermatology. 2019;5(3):141-150.`
│   depth: `1`
│   children:
│   ├── TextNode
│   │   full_match: `Gottlieb AB, Ryan C, Murase JE. Clinical considerations for the management of psoriasis in women. Int J women&#39;s dermatology. 2019;5(3):141-150.`
│   │   inner_content: `Gottlieb AB, Ryan C, Murase JE. Clinical considerations for the management of psoriasis in women. Int J women&#39;s dermatology. 2019;5(3):141-150.`├── TextNode
│   full_match: `\n`
│   inner_content: `\n`├── NumListItemNode
│   full_match: `#Chi C., Wang SH, Wojnarowska F, et al. Safety of __topical corticosteroids__ in pregnancy. Cochrane database Syst Rev. 2015;2015(10).`
│   inner_content: `Chi C., Wang SH, Wojnarowska F, et al. Safety of __topical corticosteroids__ in pregnancy. Cochrane database Syst Rev. 2015;2015(10).`
│   depth: `1`
│   children:
│   ├── TextNode
│   │   full_match: `Chi C., Wang SH, Wojnarowska F, et al. Safety of `
│   │   inner_content: `Chi C., Wang SH, Wojnarowska F, et al. Safety of `
│   ├── BoldNode
│   │   full_match: `__topical corticosteroids__`
│   │   inner_content: `topical corticosteroids`
│   │   children:
│   │   ├── TextNode
│   │   │   full_match: `topical corticosteroids`
│   │   │   inner_content: `topical corticosteroids`
│   ├── TextNode
│   │   full_match: ` in pregnancy. Cochrane database Syst Rev. 2015;2015(10).`
│   │   inner_content: ` in pregnancy. Cochrane database Syst Rev. 2015;2015(10).`├── TextNode
│   full_match: `\n`
│   inner_content: `\n`├── NumListItemNode
│   full_match: `#Murase JE, Heller MM, Butler DC. Safety of dermatologic medications in pregnancy and lactation: Part I. Pregnancy. J Am Acad Dermatol. 2014;70(3):401.e1-401.e14.`
│   inner_content: `Murase JE, Heller MM, Butler DC. Safety of dermatologic medications in pregnancy and lactation: Part I. Pregnancy. J Am Acad Dermatol. 2014;70(3):401.e1-401.e14.`
│   depth: `1`
│   children:
│   ├── TextNode
│   │   full_match: `Murase JE, Heller MM, Butler DC. Safety of dermatologic medications in pregnancy and lactation: Part I. Pregnancy. J Am Acad Dermatol. 2014;70(3):401.e1-401.e14.`
│   │   inner_content: `Murase JE, Heller MM, Butler DC. Safety of dermatologic medications in pregnancy and lactation: Part I. Pregnancy. J Am Acad Dermatol. 2014;70(3):401.e1-401.e14.`├── TextNode
│   full_match: `\n`
│   inner_content: `\n`├── NumListItemNode
│   full_match: `#Vestergaard C, Wollenberg A, Barbarot S, et al. European task force on atopic dermatitis position paper: treatment of parental atopic dermatitis during preconception, pregnancy and lactation period. J Eur Acad Dermatol Venereol. 2019;33(9):1644-1659.`
│   inner_content: `Vestergaard C, Wollenberg A, Barbarot S, et al. European task force on atopic dermatitis position paper: treatment of parental atopic dermatitis during preconception, pregnancy and lactation period. J Eur Acad Dermatol Venereol. 2019;33(9):1644-1659.`
│   depth: `1`
│   children:
│   ├── TextNode
│   │   full_match: `Vestergaard C, Wollenberg A, Barbarot S, et al. European task force on atopic dermatitis position paper: treatment of parental atopic dermatitis during preconception, pregnancy and lactation period. J Eur Acad Dermatol Venereol. 2019;33(9):1644-1659.`
│   │   inner_content: `Vestergaard C, Wollenberg A, Barbarot S, et al. European task force on atopic dermatitis position paper: treatment of parental atopic dermatitis during preconception, pregnancy and lactation period. J Eur Acad Dermatol Venereol. 2019;33(9):1644-1659.`├── HorizontalRuleNode
│   full_match: `\n---\n`
│   inner_content: `---`├── HeadingNode
│   full_match: `!!!!Founder of VitaminDWiki on Topical vitamin D for psoraisis`
│   inner_content: `Founder of VitaminDWiki on Topical vitamin D for psoraisis`
│   level: `4`
│   children:
│   ├── TextNode
│   │   full_match: `Founder of VitaminDWiki on Topical vitamin D for psoraisis`
│   │   inner_content: `Founder of VitaminDWiki on Topical vitamin D for psoraisis`├── TextNode
│   full_match: `\nHave been using it for over a decade for small psorasis on my right knee (bik injury)\nAbout 3 times a year I notice it again and re-apply a few drops of nanoemulsion Vitamin D (10,000 IU)\nMy wife also uses it for skin problems - but washes it off after about 10 minutes . She does not like the sticky feel`
│   inner_content: `\nHave been using it for over a decade for small psorasis on my right knee (bik injury)\nAbout 3 times a year I notice it again and re-apply a few drops of nanoemulsion Vitamin D (10,000 IU)\nMy wife also uses it for skin problems - but washes it off after about 10 minutes . She does not like the sticky feel`├── HorizontalRuleNode
│   full_match: `\n---\n`
│   inner_content: `---`├── HeadingNode
│   full_match: `!!!!VitaminDWiki – ((Topical Vitamin D)) category contains`
│   inner_content: `VitaminDWiki – ((Topical Vitamin D)) category contains`
│   level: `4`
│   children:
│   ├── TextNode
│   │   full_match: `VitaminDWiki – `
│   │   inner_content: `VitaminDWiki – `
│   ├── LocalLinkNode
│   │   full_match: `((Topical Vitamin D))`
│   │   inner_content: `Topical Vitamin D`
│   │   page: `Topical Vitamin D`
│   │   children:
│   │   ├── TextNode
│   │   │   full_match: `Topical Vitamin D`
│   │   │   inner_content: `Topical Vitamin D`
│   ├── TextNode
│   │   full_match: ` category contains`
│   │   inner_content: ` category contains`├── TextNode
│   full_match: `\n`
│   inner_content: `\n`├── IncludeNode
│   full_match: `{include page=&quot;Topical Vitamin D&quot; start=&quot;~tc~ start ~/tc~&quot; stop=&quot;~tc~ end ~/tc~&quot;}`
│   inner_content: ``
│   attrs_dict:
│   │   raw_content:  page=&quot;Topical Vitamin D&quot; start=&quot;~tc~ start ~/tc~&quot; stop=&quot;~tc~ end ~/tc~&quot;
│   │   page: Topical Vitamin D
│   │   start: ~tc~ start ~/tc~
│   │   stop: ~tc~ end ~/tc~
│   children:
│   ├── TextNode
│   │   full_match: ``
│   │   inner_content: ``├── HorizontalRuleNode
│   full_match: `\n---\n`
│   inner_content: `---`├── HeadingNode
│   full_match: `!!!!VitaminDWiki – ((Psoriasis)) category contains`
│   inner_content: `VitaminDWiki – ((Psoriasis)) category contains`
│   level: `4`
│   children:
│   ├── TextNode
│   │   full_match: `VitaminDWiki – `
│   │   inner_content: `VitaminDWiki – `
│   ├── LocalLinkNode
│   │   full_match: `((Psoriasis))`
│   │   inner_content: `Psoriasis`
│   │   page: `Psoriasis`
│   │   children:
│   │   ├── TextNode
│   │   │   full_match: `Psoriasis`
│   │   │   inner_content: `Psoriasis`
│   ├── TextNode
│   │   full_match: ` category contains`
│   │   inner_content: ` category contains`├── TextNode
│   full_match: `\n`
│   inner_content: `\n`├── IncludeNode
│   full_match: `{include page=&quot;Psoriasis&quot; start=&quot;~tc~ start ~/tc~&quot; stop=&quot;~tc~ end ~/tc~&quot;}`
│   inner_content: ``
│   attrs_dict:
│   │   raw_content:  page=&quot;Psoriasis&quot; start=&quot;~tc~ start ~/tc~&quot; stop=&quot;~tc~ end ~/tc~&quot;
│   │   page: Psoriasis
│   │   start: ~tc~ start ~/tc~
│   │   stop: ~tc~ end ~/tc~
│   children:
│   ├── TextNode
│   │   full_match: ``
│   │   inner_content: ``├── HorizontalRuleNode
│   full_match: `\n---\n`
│   inner_content: `---`├── HeadingNode
│   full_match: `!!!!Renu Mahtani on ((Wonders of Vitamin D - Renu Mahtani video and transcription - Feb 2022|oral treatment of Psorasis with Vitamin D))`
│   inner_content: `Renu Mahtani on ((Wonders of Vitamin D - Renu Mahtani video and transcription - Feb 2022|oral treatment of Psorasis with Vitamin D))`
│   level: `4`
│   children:
│   ├── TextNode
│   │   full_match: `Renu Mahtani on `
│   │   inner_content: `Renu Mahtani on `
│   ├── LocalLinkNode
│   │   full_match: `((Wonders of Vitamin D - Renu Mahtani video and transcription - Feb 2022|oral treatment of Psorasis with Vitamin D))`
│   │   inner_content: `Wonders of Vitamin D - Renu Mahtani video and transcription - Feb 2022|oral treatment of Psorasis with Vitamin D`
│   │   page: `Wonders of Vitamin D - Renu Mahtani video and transcription - Feb 2022|oral treatment of Psorasis with Vitamin D`
│   │   children:
│   │   ├── TextNode
│   │   │   full_match: `Wonders of Vitamin D - Renu Mahtani video and transcription - Feb 2022|oral treatment of Psorasis with Vitamin D`
│   │   │   inner_content: `Wonders of Vitamin D - Renu Mahtani video and transcription - Feb 2022|oral treatment of Psorasis with Vitamin D`├── TextNode
│   full_match: `\n`
│   inner_content: `\n`├── IncludeNode
│   full_match: `{include page=&quot;Wonders of Vitamin D - Renu Mahtani video and transcription - Feb 2022&quot; start=&quot;~tc~ start ~/tc~&quot; stop=&quot;~tc~ end ~/tc~&quot;}`
│   inner_content: ``
│   attrs_dict:
│   │   raw_content:  page=&quot;Wonders of Vitamin D - Renu Mahtani video and transcription - Feb 2022&quot; start=&quot;~tc~ start ~/tc~&quot; stop=&quot;~tc~ end ~/tc~&quot;
│   │   page: Wonders of Vitamin D - Renu Mahtani video and transcription - Feb 2022
│   │   start: ~tc~ start ~/tc~
│   │   stop: ~tc~ end ~/tc~
│   children:
│   ├── TextNode
│   │   full_match: ``
│   │   inner_content: ``├── HorizontalRuleNode
│   full_match: `\n---\n`
│   inner_content: `---`├── HeadingNode
│   full_match: `!!!!VitaminDWiki – ((Nanoemulsion Vitamin D may be a substantially better form)) updated March 2019`
│   inner_content: `VitaminDWiki – ((Nanoemulsion Vitamin D may be a substantially better form)) updated March 2019`
│   level: `4`
│   children:
│   ├── TextNode
│   │   full_match: `VitaminDWiki – `
│   │   inner_content: `VitaminDWiki – `
│   ├── LocalLinkNode
│   │   full_match: `((Nanoemulsion Vitamin D may be a substantially better form))`
│   │   inner_content: `Nanoemulsion Vitamin D may be a substantially better form`
│   │   page: `Nanoemulsion Vitamin D may be a substantially better form`
│   │   children:
│   │   ├── TextNode
│   │   │   full_match: `Nanoemulsion Vitamin D may be a substantially better form`
│   │   │   inner_content: `Nanoemulsion Vitamin D may be a substantially better form`
│   ├── TextNode
│   │   full_match: ` updated March 2019`
│   │   inner_content: ` updated March 2019`├── TextNode
│   full_match: `\n`
│   inner_content: `\n`├── IncludeNode
│   full_match: `{include page=&quot;Nanoemulsion Vitamin D may be a substantially better form&quot; start=&quot;~tc~ start ~/tc~&quot; stop=&quot;~tc~ end ~/tc~&quot;}`
│   inner_content: ``
│   attrs_dict:
│   │   raw_content:  page=&quot;Nanoemulsion Vitamin D may be a substantially better form&quot; start=&quot;~tc~ start ~/tc~&quot; stop=&quot;~tc~ end ~/tc~&quot;
│   │   page: Nanoemulsion Vitamin D may be a substantially better form
│   │   start: ~tc~ start ~/tc~
│   │   stop: ~tc~ end ~/tc~
│   children:
│   ├── TextNode
│   │   full_match: ``
│   │   inner_content: ``├── TextNode
│   full_match: `\n - - - - - - - - - - - - - -\n`
│   inner_content: `\n - - - - - - - - - - - - - -\n`├── IncludeNode
│   full_match: `{include page=&quot;Nanoemulsion Vitamin D may be a substantially better form&quot; start=&quot;~tc~ start2 ~/tc~&quot; stop=&quot;~tc~ end2 ~/tc~&quot;}`
│   inner_content: ``
│   attrs_dict:
│   │   raw_content:  page=&quot;Nanoemulsion Vitamin D may be a substantially better form&quot; start=&quot;~tc~ start2 ~/tc~&quot; stop=&quot;~tc~ end2 ~/tc~&quot;
│   │   page: Nanoemulsion Vitamin D may be a substantially better form
│   │   start: ~tc~ start2 ~/tc~
│   │   stop: ~tc~ end2 ~/tc~
│   children:
│   ├── TextNode
│   │   full_match: ``
│   │   inner_content: ``├── TextNode
│   full_match: `\n`
│   inner_content: `\n`

Original Tiki:
-------------
{DIV(class=&quot;lefth4&quot;)}{maketoc Title=&quot;&quot;}{DIV} 
---
!!!!Topical treatment of psoriasis vulgaris
J Dtsch Dermatol Ges . 2023 May 26. doi: 10.1111/ddg.15042 ~hs~ PDF is behind a paywall
Lejla Ramic 1, Paul Sator 1

Topical therapy plays an important role in the treatment of psoriasis. It is the gold standard in mild psoriasis cases and is also recommended in addition to UV and systemic therapy in cases of moderate to severe psoriasis. In this overview article we summarize the current therapeutic options, taking into account special localizations (scalp, facial, intertriginous/genital, or palmoplantar lesions) and situations (hyperkeratotic or inflammatory forms), as well as the therapy options during pregnancy and breastfeeding. In the initial phase, the combination of topical corticosteroids and vitamin D analogues has proven to be the therapy of choice, as well as monotherapy in each case. In maintenance therapy, fixed combination therapy is recommended once or twice a week. In addition to the right choice of active substances, the choice of the right formulation also plays an important role. 
To increase adherence, it is very important to consider the personal preferences and experiences of the patient. If topical therapy does not lead to a satisfactory result, additional UV therapy or systemic therapy should be considered.

!!!!!56 References
#Nast A, Altenburg A, Augustin M, et al. German S3-Guideline on the treatment of Psoriasis vulgaris, adapted from EuroGuiDerm - Part 1: Treatment goals and treatment recommendations. J Dtsch Dermatol Ges. 2021;19(6):934-1150.
#Armstrong AW, Read C. Pathophysiology, clinical presentation, and treatment of psoriasis: a review. J Am Med Assoc. 2020;323(19):1945-1960.
#Boehncke WH, Schön MP. Psoriasis. Lancet. 2015;386(9997):983-994.
#Mrowietz U, Kragballe K, Reich K, et al. Definition of treatment goals for moderate to severe psoriasis: A European consensus. Arch Dermatol Res. 2011;303(1):1-10.
#Langenbruch A, Radtke MA, Jacobi A, et al. Quality of psoriasis care in Germany: results of the national health care study “PsoHealth3”. Arch Dermatol Res. 2016;308(6):401-408.
#Devaux S, Castela A, Archier E, et al. Adherence to __topical__ treatment in psoriasis: a systematic literature review. J Eur Acad Dermatol Venereol. 2012;26(Suppl 3):61-67.
#Luger T, Seite S, Humbert P, et al. Recommendations for adjunctive basic skin care in patients with psoriasis. Eur J Dermatol. 2014;24(2):194-200.
#Fluhr JW, Cavallotti C, Berardesca E. Emollients, moisturizers, and keratolytic agents in psoriasis. Clin Dermatol. 2008;26(4):380-386.
#M Lebwohl. The role of salicylic acid in the treatment of psoriasis. Int J Dermatol. 1999;38(1):16-24.
#Taylor JR, Halprin KM. percutaneous absorption of salicylic acid. Arch Dermatol. 1975;111(6):740-743.
#Lew BL, Cho Y, Kim J, et al. Ceramides and cell signaling molecules in psoriatic epidermis: reduced levels of ceramides, PKC-alpha, and JNK. J Korean Med Sci. 2006;21(1):95-99.
#Vavrova K, Hrabalek A, Mac-Mary S, et al. Ceramide analogues 142S4 selectively recovers perturbed human skin barrier. Br J Dermatol. 2007; 157(4): 704-712.
#Levine D, Even-Chen Z, Lipets I, et al. Pilot, multicenter, double-blind, randomized placebo-controlled bilateral comparative study of a combination of calcipotriene and nicotinamide for the treatment of psoriasis. J Am Acad Dermatol. 2010;63(5):775-781.
#Choudhary V, Kaddour-Djebbar I, Custer VE, et al. Glycerol improves skin lesion development in the imiquimod mouse model of psoriasis: experimental confirmation of anecdotal reports from patients with psoriasis. Int J Mol Sci. 2021;22(16):8749.
#Seite S. Thermal waters as cosmeceuticals: La Roche-Posay thermal spring water example. Clin Cosmet Investig Dermatol. 2013;6:23-28.
#Siegfried EC, Jaworski JC, Kaiser JD, Hebert AA. Systematic review of published trials: long-term safety of __topical corticosteroids__ and __topical__ calcineurin inhibitors in pediatric patients with atopic dermatitis. BMC Pediatr. 2016;16:75.
#Douglas WS, Poulin Y, Decroix J, et al. A new calcipotriol/betamethasone formulation with rapid onset of action was superior to monotherapy with betamethasone dipropionate or calcipotriol in psoriasis vulgaris. Acta Derm Venereol. 2002;82:131-135.
#Papp KA, Guenther L, Boyden B, et al. Early onset of action and efficacy of a combination of calcipotriene and betamethasone dipropionate in the treatment of psoriasis. J Am Acad Dermatol. 2003;48:48-54.
#Gottlieb AB, Ford RO, Spellman MC. The efficacy and tolerability of clobetasol propionate foam 0.05% in the treatment of mild to moderate plaque-type psoriasis of nonscalp regions. J Cutan Med Surg. 2003;7:185-192.
#Weston WL, Fennessey PV, Morelli J, et al. Comparison of hypothalamus-pituitary-adrenal axis suppression from superpotent __topical steroids__ by standard endocrine function testing and gas chromatographic mass spectrometry. J Invest Dermatol. 1988;90:532-535.
#Wilsmann-Theis D, Gerdes S, Körber A, et al. Topische Therapie der Psoriasis.1. Auflage, Bremen: UNI-MED, 2016.
#Gerritsen MJ, Van De Kerkhof PC, Langner A. Long-term safety of __topical__ calcitriol 3 microg g(-1) ointment. Br J Dermatol. 2001;144(Suppl 58):17-19.
#Amichai B. Psoriasis of the glans penis in a child successfully treated with Elidel (pimecrolimus) cream. J Eur Acad Dermatol Venereol. 2004;18(6):742-743.
#Freeman AK, Linowski GJ, Brady C, et al. Tacrolimus ointment for the treatment of psoriasis on the face and intertriginous areas. J Am Acad Dermatol. 2003;48(4):564-568.
#Gribetz C, Ling M, Lebwohl M, et al. Pimecrolimus cream 1% in the treatment of intertriginous psoriasis: A double-blind, randomized study. J Am Acad Dermatol. 2004;51(5):731-738.
#Remitz A, Reitamo S, Erkko P, et al. Tacrolimus ointment improves psoriasis in a microplaque assay. Br J Dermatol. 1999;141(1):103-107.
#Zonneveld IM, Rubins A, Jablonska S, et al. __topical__ tacrolimus is not effective in chronic plaque psoriasis. A pilot study. Arch Dermatol. 1998;134(9):1101-1102.
#Weischer M, Röcken M, Berneburg M. Calcineurin inhibitors and rapamycin: cancer protection or promotion? Exp Dermatol. 2007;16(5):385-393.
#Reitamo S, Rissanen J, Remitz A, et al. Tacrolimus ointment does not affect collagen synthesis: results of a single-center randomized trial. J Invest Dermatol. 1998;111(3):396-398.
#Lebwohl M, Freeman AK, Chapman MS, et al. Tacrolimus ointment is effective for facial and intertriginous psoriasis. J Am Acad Dermatol. 2004;51(5):723-730.
#Doelker L, Tran C, Gkomouzas A, et al. Production and clearance of cyclobutane dipyrimidine dimers in UV-irradiated skin pretreated with 1% pimecrolimus or 0.1% triamcinolone acetonide creams in normal and atopic patients. Exp Dermatol. 2006;15:342-346.
#Mrowietz U, Jessat H, Schwarz A, Schwarz T. Anthralin (dithranol) in vitro inhibits human monocytes to secrete IL-6, IL-8 and TNF-α, but not IL-1. Br J Dermatol. 1997;136(4):542-547.
#Painsi C, Patscheider M, Inzinger M, et al. Die Behandlung der Psoriasis mit klassischer, stationärer Dithranol-Therapie: eine retrospektive Patientenbefragung. J Dtsch Dermatol Ges. 2015;13(11):1156-1163.
#Vtama (tapinarof) cream, for __topical__ use. US FDA approved product information; Long Beach, CA: Dermavant Sciences, Inc, 2022.
#Lebwohl MG, Stein Gold L, Strober B, et al. Phase 3 trials of tapinarof cream for plaque psoriasis. N Engl J Med. 2021;385:2219.
#Lebwohl MG, Papp KA, Stein Gold L, et al. Trial of roflumilast cream for chronic plaque psoriasis. N Engl J Med. 2020;383(3):229-239.
#Körber A, Wilsmann-Theis D, Augustun M, et al. Topische Therapie bei Psoriasis vulgaris - ein Behandlungspfad. J Dtsch Dermatol Ges. 2019;17(Suppl 4):3-14.
#Ruzicka T, Lorenz B. Comparison of calcipotriol monotherapy and a combination of calcipotriol and betamethasone valerate after 2 weeks’ treatment with calcipotriol in the __topical__ therapy of psoriasis vulgaris: a multicentre, double-blind, randomized study. Br J Dermatol. 1998;138(2):254-258.
#Kragballe K, Barnes L, Hamberg KJ, et al. Calcipotriol cream with or without concurrent __topical corticosteroid__ in psoriasis: tolerability and efficacy. Br J Dermatol. 1998;139(4):649-654.
#Radtke MA, Herberger K, Kornek T, Augustin M. [Calcipotriol plus betamethasone dipropionate gel in the treatment of scalp psoriasis. A review]. Hautarzt. 2010;61(9):770-775.
#Leonardi C, Bagel J, Yamauchi P, Pariser D, et al. Efficacy and safety of calcipotriene plus betamethasone dipropionate aerosol foam in patients with psoriasis vulgaris - a randomized phase III study (PSO-FAST). J Drugs Dermatol. 2015;14(12):1468-1477.
#Lebwohl M, Tyring S, Bukhalo M, et al. Fixed combination aerosol foam calcipotriene 0.005% (cal) plus betamethasone dipropionate0.064% (bd) is more efficacious than Cal or BD aerosol foam alone for psoriasis vulgaris: a randomized, double-blind, multicenter, three-arm, phase 2 study. J Clin Aesthet Dermatol. 2016;9(2):34.
#Koo J, Tyring S, Werschler WP, et al. Superior efficacy of calcipotriene and betamethasone dipropionate aerosol foam versus ointment in patients with psoriasis vulgaris - A randomized phase II study. J Dermatolog Treat. 2016;27(2):120-127.
#Paul C, Stein Gold L, Cambazard F, et al. Calcipotriol plus betamethasone dipropionate aerosol foam provides superior efficacy vs. gel in patients with psoriasis vulgaris: randomized, controlled PSO-ABLE study. J Eur Acad Dermatol Venereol. 2017;31(1):119-126.
#Lind M, Nielsen KT, Schefe LH, et al. Supersaturation of calcipotriene and betamethasone dipropionate in a novel aerosol foam formulation for __topical__ treatment of psoriasis provides enhanced bioavailability of the active ingredients. Dermatol Ther (Heidelb). 2016;6(3):413-425.
#Samarasekera EJ, Sawyer L, Wonderling D, et al. __topical__ therapies for the treatment of plaque psoriasis: systematic review and network metaanalyses. Br J Dermatol. 2013;168(5):954-967.
#Mason AR, Mason J, Cork M, et al. __topical__ treatments for chronic plaque psoriasis. Cochrane database Syst Rev. 2009;(2):CD005028.
#Saraceno R, Camplone G, D&#39;Agostino M, et al. Efficacy and maintenance strategies of two-compound formulation calcipotriol and betamethasone dipropionate gel (Xamiol® gel) in the treatment of scalp psoriasis: results from a study in 885 patients. J Dermatolog Treat. 2014;25(1):30-33.
#Stein Gold L, Alonso-Llamazares J, Lacour JP, et al. PSO-LONG: Design of a novel, 12-month clinical trial of __topical__, proactive maintenance with twice-weekly Cal/BD foam in psoriasis. Adv Ther. 2020;37(11):4730-4753.
#van de Kerkhof PC, de Hoop D, de Korte J, Kuipers MV. Scalp psoriasis, clinical presentations and therapeutic management. Dermatology. 1998;197(4):326-334.
#Schlager JG, Rosumeck S, Werner RN, et al. __topical__ treatments for scalp psoriasis: summary of a Cochrane Systematic Review. Br J Dermatol. 2017;176(3):604-614.
#Schlager JG, Rosumeck S, Werner RN, et al. __topical__ treatments for scalp psoriasis. Vol. 2016, Cochrane Database of Systematic Reviews. John Wiley and Sons Ltd. 2016;2:CD009687.
#Chan CS, Van Voorhees AS, Lebwohl MG, et al. Treatment of severe scalp psoriasis: From the Medical Board of the National Psoriasis Foundation. J Am Acad Dermatol. 2009;60(6):962-971.
#Jacobi A, Braeutigam M, Mahler V, et al. Pimecrolimus 1% cream in the treatment of facial psoriasis: A 16-week open-label study. Dermatology. 2008;216(2):133-136.
#Jiaravuthisan MM, Sasseville D, Vender RB, et al. Psoriasis of the nail: Anatomy, pathology, clinical presentation, and a review of the literature on therapy. J Am Acad Dermatol. 2007;57(1):1-27.
#Williamson L, Dalbeth N, Dockerty JL, et al. Extended report: nail disease in psoriatic arthritis - clinically important, potentially treatable and often overlooked. Rheumatology (Oxford). 2004;43(6):790-794.
#De Berker D. Management of psoriatic nail disease. Semin Cutan Med Surg. 2009;28(1):39-43.
#Pasch MC. Nail Psoriasis: A review of treatment options. Drugs. 2016;76(6):675-705.
#Rigopoulos D, Gregoriou S, Daniel Iii CR, et al. Treatment of nail psoriasis with a two-compound formulation of calcipotriol plus betamethasone dipropionate ointment. Dermatology. 2009;218(4):338-341.
#Rigopoulos D, Ioannides D, Prastitis N, Katsambas A. Nail psoriasis: a combined treatment using calcipotriol cream and clobetasol propionate cream. Acta Derm Venereol. 2002;82(2):140.
#Tzung TY, Chen CY, Yang CY, et al. Calcipotriol used as monotherapy or combination therapy with betamethasone dipropionate in the treatment of nail psoriasis. Acta Derm Venereol. 2008;88(3):279-280.
#Chi CC, Wang SH, Mayon-White R, Wojnarowska F. Pregnancy outcomes after maternal exposure to __topical corticosteroids__: a UK population-based cohort study. JAMA dermatology. 2013;149(11):1274-1280.
#Gottlieb AB, Ryan C, Murase JE. Clinical considerations for the management of psoriasis in women. Int J women&#39;s dermatology. 2019;5(3):141-150.
#Chi C., Wang SH, Wojnarowska F, et al. Safety of __topical corticosteroids__ in pregnancy. Cochrane database Syst Rev. 2015;2015(10).
#Murase JE, Heller MM, Butler DC. Safety of dermatologic medications in pregnancy and lactation: Part I. Pregnancy. J Am Acad Dermatol. 2014;70(3):401.e1-401.e14.
#Vestergaard C, Wollenberg A, Barbarot S, et al. European task force on atopic dermatitis position paper: treatment of parental atopic dermatitis during preconception, pregnancy and lactation period. J Eur Acad Dermatol Venereol. 2019;33(9):1644-1659.
---
!!!!Founder of VitaminDWiki on Topical vitamin D for psoraisis
Have been using it for over a decade for small psorasis on my right knee (bik injury)
About 3 times a year I notice it again and re-apply a few drops of nanoemulsion Vitamin D (10,000 IU)
My wife also uses it for skin problems - but washes it off after about 10 minutes . She does not like the sticky feel
---
!!!!VitaminDWiki – ((Topical Vitamin D)) category contains
{include page=&quot;Topical Vitamin D&quot; start=&quot;~tc~ start ~/tc~&quot; stop=&quot;~tc~ end ~/tc~&quot;}
---
!!!!VitaminDWiki – ((Psoriasis)) category contains
{include page=&quot;Psoriasis&quot; start=&quot;~tc~ start ~/tc~&quot; stop=&quot;~tc~ end ~/tc~&quot;}
---
!!!!Renu Mahtani on ((Wonders of Vitamin D - Renu Mahtani video and transcription - Feb 2022|oral treatment of Psorasis with Vitamin D))
{include page=&quot;Wonders of Vitamin D - Renu Mahtani video and transcription - Feb 2022&quot; start=&quot;~tc~ start ~/tc~&quot; stop=&quot;~tc~ end ~/tc~&quot;}
---
!!!!VitaminDWiki – ((Nanoemulsion Vitamin D may be a substantially better form)) updated March 2019
{include page=&quot;Nanoemulsion Vitamin D may be a substantially better form&quot; start=&quot;~tc~ start ~/tc~&quot; stop=&quot;~tc~ end ~/tc~&quot;}
 - - - - - - - - - - - - - -
{include page=&quot;Nanoemulsion Vitamin D may be a substantially better form&quot; start=&quot;~tc~ start2 ~/tc~&quot; stop=&quot;~tc~ end2 ~/tc~&quot;}

</code>
</pre>

    </article>

        </div>
    </div>

    <script src="/js/lightspa.js?v=1742566339"></script>
    <script>
        
        const spa = new LightSPA({
            mainContentSelector: '[role="main"]',
            navigationSelector: '[data-spa-nav]'
        });

        
        const search = new Search({
            documentsUrl: '\/js\/search_documents.json?v=1742566339',
            indexUrl: '\/js\/search_index.json?v=1742566339'
        });
    </script>
</body>
</html>